

# **CURRICULUM VITAE**

**Professor Peter John Grant**

## PERSONAL DETAILS

**Surname:** GRANT

**First names:** Peter John

**Birthdate:** 29th July 1952

**Nationality:** British

**Education:** 1963-1971  
Hove County Grammar School, Hove, Sussex

**Medical Education:** 1971-1976  
Faculty of Medicine, University of Bristol

**Degrees:** 1976 MBChB  
1987 MD Bristol University

**Postgraduate Qualifications:** 1981 MRCP (UK)  
1995 FRCP (UK)  
2003 FRCP (Edinburgh)

**GMC Registration:** Full, No: 2299660/CAPH, Date of first registration: 31<sup>st</sup> August 1977

**Medical Defence Union:** Full, No: 125987B

## PRESENT POST

since December 2000: **Professor of Medicine**  
(University of Leeds) and  
**Honorary Consultant Physician**  
(United Leeds Teaching Hospitals NHS Trust)

and also

since October 1999: **Head of the Academic Unit of Molecular Vascular Medicine**  
(School of Medicine, University of Leeds)

## PREVIOUS APPOINTMENTS

Mar 96-Dec 00	Professor of Molecular Vascular Medicine and Honorary Consultant Physician	University of Leeds Leeds Teaching Hospitals NHS Trust
Aug 89-Feb 96	Senior Lecturer in Medicine and Honorary Consultant Physician	University of Leeds Leeds Teaching Hospitals NHS Trust
July 88-Aug 89	Medicin Assistant Boursier	Central Hospital Universitaire Vaudois Lausanne, Switzerland
Oct 85-June 88	Tutor and Honorary Senior Registrar (Professorial Medical Unit)	University of Leeds Leeds General Infirmary
Aug 83-Aug 85	Wellcome Research Fellow and Honorary Registrar (Professorial Medical Unit)	Leeds General Infirmary
Aug 82-Jul 83	Registrar (Professorial Medical Unit)	Leeds General Infirmary
Sept 81-Jul 82	Registrar (Medicine)	Airedale General Hospital West Yorkshire
Feb 80-Feb 81	Senior House Officer (Medicine)	Southmead Hospital Bristol
Sept 78-Jan 80	Senior House Officer (Medicine)	George Eliot Hospital Nuneaton, Warwicks
Aug 77-Feb 78	Senior House Officer (A&E)	Bristol Royal Infirmary
Feb 77-July 77 Hospital	House Physician	Bristol General
Aug 76-Jan 77	House Surgeon	Frenchay Hospital, Bristol

## FUNDING OBTAINED (SINCE 1989)

### Grants from Charities:

1 Nov 2003- 31 Jan 2005	<b>Diabetes UK</b> (RD03/0002622) <i>Translational regulation of glyoxalase II splice variants and subcellular localization of glyoxalase II isoforms: Implications for reduced glutathione metabolism and regulation of intracellular advanced glycation products</i> Funding for a Research Assistant (Dr L McCormack)	£57,808
Nov 2003- Oct 2006	<b>British Heart Foundation Project Grant</b> (PG/03/080/15731) (with Drs RJ Pease and RAS Ariëns) <i>Is factor XIIIa actively secreted from haemopoietic cells?</i> Funding for a Research Fellow (Mr P Cordell)	£131,594
Oct 2003- Sept 2005	<b>British Heart Foundation Junior Research Fellowship</b> (FS/03/056) (with Dr A Carter) <i>Inflammation in S Asian relatives of subjects with type 2 diabetes mellitus</i> Funding for a Junior Research Fellow (Dr R Somani)	£89,424
Oct 2003- Sept 2006	<b>British Heart Foundation Programme Grant</b> (RG/03/004) (with Drs H Philippou and RAS Ariëns) <i>Molecular analysis of factor XIII/fibrinogen interactions in the regulation of fibrin assembly</i> Funding for a Research Fellow (Dr P Adamson) and a Technician (Ms K Smith)	£240,122
March 2003- Feb 2005	<b>Diabetes UK</b> (RD02/0002492) <i>Glycation of fibrinogen in relation to fibrin structure/function: Effects and mechanisms</i> Clinical Training Fellowship (Dr E Dunn)	£103,901
Oct 2002- Sept 2005	<b>British Heart Foundation</b> (with Professor NM Hooper and Dr AM Carter, Leeds) <i>Molecular characterization of the aminopeptidase P gene promoter.</i> Funding to support a PhD student (Ms A Jones)	£65,650
Sept 2002- Aug 2005	<b>British Heart Foundation Project Grant</b> (PG/02/124/14502) (with Dr RAS Ariëns and Dr AM Carter, Leeds) <i>Role of factor XIII dependent cross-linking in fibrin clot structure and function: site-directed mutagenesis of cross-linking sites.</i> Funding to supporting a Technician (Ms K Standeven)	£133,629

Sept 2002- Aug 2005	<b>British Heart Foundation</b> (FS/02/069/14408) (with Dr RAS Ariëns, Leeds) <i>Identification of factor XIII A-subunit residues involving B-subunit binding.</i> Clinical PhD Studentship (Dr MP Dissanayake)	£129,613
Aug 2002- July 2007	<b>The Wellcome Trust</b> (068181/Z/02/Z) (with Dr SCL Gough, Prof JA Frankly, Dr JM Heward, Dr SHS Pearce, Prof K Chatterjee, Dr J Worthington, Prof A Hattersley and Dr A Allahabadia) <i>A nationwide DNA collection from index cases and families with autoimmune thyroid disease.</i>	£783,450 to all centres
Sept 2002- Aug 2005	<b>Diabetes UK</b> (RD02/0002438) <i>Molecular regulation of EN-RAGE and its role in vascular risk clustering and myocardial infarction</i> Funding to support a Technician (Ms J Brown) and a part-time Senior Research Fellow (Dr S Futers)	£100,685
Aug 2002- July 2005	<b>European Foundation for the Study of Diabetes and Servier Laboratories</b> <i>Do genetic variants of HNF1<math>\alpha</math> explain the genetic pleiotropy between insulin resistance and coagulation.</i> Funding to support a PhD student (Ms P Karatza)	100,000 Euros
Oct 2002- Dec 2003	<b>National Heart Research Fund</b> <i>Investigation of the molecular processes of fibrin clot formation and dissolution using the atomic force microscope.</i> Funding to support the visit of Prof J Weisel, Philadelphia, to the Unit in Leeds.	£7,781
June 2003- May 2004	<b>British Heart Foundation</b> (FS/200023 extension) (with Dr Ariëns, Leeds) <i>Investigation of the molecular processes of fibrin clot formation and dissolution using the atomic force microscope.</i> Funding for a Junior Research Fellow (Dr B Lim)	£40,250
May 2002- April 2003	<b>The Wellcome Trust. Entry Level Training Fellowship</b> (067867/Z/02/Z) (with Dr Carter, Leeds) <i>C/EBP<math>\alpha</math> promoter polymorphisms and heritability of insulin resistance and haemostasis</i> Funding for a Research Fellow (Dr U Prasad)	£55,549
Nov 2001- Oct 2004	<b>British Heart Foundation</b> (FS02/010) (with Dr Ariëns, Leeds) <i>Identification of factor XIII residues involved in thrombin interaction.</i> Funding for a PhD Student (Ms S Mackenzie)	£66,045
March 2002-	<b>The Wellcome Trust. Entry Level Training Fellowship</b>	£43,842

Feb 2003	(066340/Z/01/A) <i>Assessment of the genetics of fibrin clot structure and function.</i> Funding for a Research Fellow (Dr E Dunn)	
Oct 2001- Sept 2004	<b>British Heart Foundation</b> (FS2001/065) (with Drs Hudson and Carter, Leeds) <i>Characterisation of the transcriptional regulation of genetic variants of the receptor for advanced glycation end products</i> Funding for a PhD Student (Ms S Dolling)	£61,702
May 2001- April 2004	<b>British Heart Foundation</b> (FS2001/037) (with Dr Carter, Leeds) <i>CCAAT/Enhancer binding protein b genetic variants and gene regulation: implications for haemostasis and thrombosis.</i> Funding for a PhD Student (Ms J Bostock)	£61,558
Feb 2001- Jan 2004	<b>British Heart Foundation</b> (FS2001/012) (with Dr Carter, Leeds) <i><math>\beta</math>3 integrin gene polymorphisms, gene regulation and vascular risk</i> Funding for a PhD Student (Ms K Payne)	£60,698
Feb 2001 – Jan 2003	<b>British Heart Foundation</b> (FS2001/003) (with Professor Wild, Epidemiology, Leeds) <i>Role of polymorphisms in the glutathione 5-transferase A4-4 gene and susceptibility to vascular disease</i> Funding for a Junior Research Fellow (Dr M Wilson)	£53,740
Jan 2001- Dec 2001	<b>Medical Research Council Joint Research Equipment Initiative</b> (G0000624/53089) (with Drs Carter and Ariëns, Leeds) <i>Characterisation of polymorphic variants: influence on fibrin formation, fibrinolysis and cellular receptor expression.</i>	Total £250,540 (£125,270 – MRC contribution)
Jan 2001- Dec 2001	<b>Medical Research Council Joint Research Equipment Initiative</b> (with Professor Findlay, Biochemistry, Leeds) <i>Establishment of a proteomics facility for biological and medical research in Leeds</i>	£573,399
Dec 2000 – Nov 2002	<b>British Heart Foundation</b> (PG2000/114) (with Dr Hooper and Prof Turner) <i>A novel human homolog of angiotensin converting enzyme (ACE): evaluation of its role in angiotensin metabolism</i> Funding for a Research Fellow (Dr G Rice)	£82,953
Dec 2000- Nov 2001	<b>British Heart Foundation</b> (FS/98063 extension) <i>Fibrin structure and function in first degree relatives of</i>	£38,474

*subjects with multivessel coronary artery disease*  
(continuation of FS/98063, Funding for Dr J Mills)

October 2000	<b>Gemini-Genomics plc</b> <i>Grant in Aid</i>	£250,000
July 2000- June 2003	<b>Medical Research Council Clinical Training Fellowship</b> (G84/5759) <i>The development of a knockout glyoxalase gene 1 mouse model for the investigation of the functional significance of glyoxalase 1 in atherosclerosis</i> (Fellowship for Dr Christopher Gale)	£100,000
June 2000- May 2002	<b>British Heart Foundation</b> (FS/2000023) <i>Analysis of the effects of common coding polymorphisms in the A<math>\alpha</math> and B<math>\beta</math> chains of fibrinogen on fibrin structure and function</i> Funding for a Junior Research Fellow (Dr B Lim)	£74,515
Apr 2000- Mar 2004	<b>Medical Research Council Clinical Scientist Fellowship</b> (G108/369) <i>The molecular genetics of the Factor XIII B subunit gene and its role in thrombotic disorders</i> (Fellowship for Dr Andrew Catto)	£486,000
Apr 2000- Mar 2001	<b>Medical Research Council Joint Research Equipment Initiative and Gemini Holdings plc</b> (G9900904) with Dr Ariens <i>Studies of the haemostatic system in vascular disease: gene polymorphisms to protein structure and function.</i>	£112,181
Mar 2000- Feb 2002	<b>British Heart Foundation</b> (FS/2000006) with Dr Chris Wild <i>The role of DNA damage in the development of atheroma and myocardial infarction.</i> Funding for a Junior Research Fellow (Dr J Winter)	£83,109
Feb 2000- Jan 2002	<b>British Heart Foundation</b> (FS/2000007) <i>Functional analysis of polymorphisms in the RAGE gene and their relation to myocardial infarction.</i> Funding for a Junior Research Fellow (Mr B Hudson)	£51,979
Jan 2000	<b>Gemini Holdings plc</b> <i>Grant in Aid</i>	£30,000
Feb 1999- Jan 2001	<b>Sir Jules Thorn Charitable Trust 998/26A)</b> <i>Functional characterization of the factor XIIIa promoter and its role in vascular disorders in man.</i> Funding for a Research Fellow (Dr TS Futers)	£76,318
Aug 1999- July 2001	<b>British Heart Foundation</b> (PG/99082) with Dr Ariens	£62,691

	<i>Molecular interactions between fibrinogen and factor XIII: effects of A<math>\alpha</math> Thr312Ala, advanced glycation end-product formation and metformin on the binding, activation and cross-linking reactions.</i> Funding for a Technician (Ms K Standeven)	
Aug 1999- July 2002	<b>British Heart Foundation</b> (PG/99084) with Dr Futers <i>Molecular Characteristics of the factor X gene and relationships to circulating factor X concentrations and thrombotic disease.</i> Funding for a Research Fellow (Dr L McCormack)	£126,565
Jan 1999- Dec 2001	<b>British Heart Foundation</b> (FS/99010) with Drs Snieder and Spector (St Thomas' Hospital) <i>A twin study of thrombotic aspects of insulin resistance syndrome: determination of genetic and environmental contribution to thrombotic risk</i> Funding for a Clinical PhD Student	£50,694
Jan 1999- Dec 2001	<b>British Heart Foundation</b> (PG/98102) <i>Factor XIII Val34Leu and cardiovascular disease: Genotype frequencies and gene environment interactions in patients with myocardial infarction and venous thrombosis: A collaboration with the US Physicians Study</i> Funding for a Project Grant	£170,148
Dec 1998- Nov 2000	<b>National Heart Research Fund</b> <i>The molecular genetics of von Willebrand factor and its role in myocardial infarction and deep vein thrombosis: A collaboration with the US Physicians Study</i> Funding for a Research Assistant (Ms G Rice)	£58,422
Dec 1998- Nov 2000	<b>British Heart Foundation</b> (FS/98063) <i>Cardiovascular risk factor clustering in the first-degree relatives of subjects with multi- vessel coronary artery disease.</i> Funding for a Junior Research Fellow (Dr J Mills)	£70,235
Dec 1998- Nov 2001	<b>British Heart Foundation</b> (PG/98104) <i>Studies of the biochemistry of factor XIII Val34Leu: Characterisation of activation rates and cross-linking activities of Val<sup>34</sup> and Leu<sup>34</sup>-factor XIII.</i> Funding for a Project Grant (Dr R Ariens)	£106,792
Oct 1998- Sept 1999	<b>National Heart Research Fund</b> <i>Prothrombin gene regulation: a model for the investigation of the functional role of sequence variation within the 5' and 3' gene regulatory regions.</i> Funding for a Clinical Scientist (Dr AM Carter)	£30,571
Oct 1998-	<b>Gemini Holdings plc</b>	£120,000

Sept 1999	<i>The heritability of coagulation factors: A twin study</i>	
Oct 1998- Sept 2001	<b>British Heart Foundation</b> (FS/98059) <i>The Factor XIII<sup>B</sup> subunit gene: isolation and functional characterisation of the promoter region and the role of allelic variants in cardiovascular disease</i> Funding for a Clinical PhD Student (Dr N Quinn)	£139,068
Sept 1998- Aug 2001	<b>National Heart Research Fund</b> <i>The role of coagulation factor X and its newly identified receptor EPR-1 in the pathogenesis of heart disease</i> Funding for a PhD Student (Ms T Akinbola)	£41,809
Aug 1998- July 2000	<b>British Heart Foundation</b> (FS/98027) <i>Functional characterisation of polymorphisms in the tissue plasminogen activator gene promoter and relationship to myocardial infarction</i> Funding for a Junior Research Fellow (Dr J Blaxill)	£86,826
Jan 1998- Dec 2000	<b>British Heart Foundation</b> (FS/97042) <i>The role of DNA damage in coronary heart disease.</i> Funding for a PhD Student (Mr M Wilson)	£55,583
Sept and Oct 1997	<b>Shield Diagnostics</b> <i>Grant in Aid: The roles of FXII and FXIII in vascular disorders.</i>	£286,500
Sept 1997- Aug 2000	<b>British Heart Foundation</b> (PG/97081) <i>Identification and functional activity of polymorphisms in binding regions of proteins involved in platelet/ligand interactions and their role in atherothrombotic cardiovascular disease.</i>	£85,331
Aug 1997- July 1999	<b>British Heart Foundation</b> (FS/97032) <i>The role of factor XIII<sup>Val34Leu</sup> in myocardial infarction in male Asian subjects: a case control study.</i> Funding for a Junior Research Fellow (Dr D Warner)	£76,116
Dec 1996- June 1998	<b>The Stroke Association</b> (17/96) <i>Polymorphisms of the fibrinogen and platelet IIb/IIIa gene in relation to stroke subtype fibrinogen levels in post stroke mortality</i> Funding for a Clinical Scientist (Dr A Carter)	£45,589
Sept 1996- Aug 1998	<b>National Heart Research Fund</b> <i>Molecular screening and functional analysis of the ACE gene: identification of the functional site controlling ACE levels and its relation to coronary artery disease.</i>	£37,803

Sept 1995- Aug 1997	<b>National Heart Research Fund</b> <i>The role of the angiotensin converting enzyme gene in the pathogenesis of coronary artery disease in ethnic groups.</i> Funding for a Post-Doctoral Research Fellow (Dr C Foy)	£65,499
Aug 1996- July 1999	<b>The Stroke Association (SA7/96)</b> (with Catto A, Bamford J, Young J and Bavington J) <i>Environmental and genetic determinants of cardiovascular risk factors in the first degree relatives of Asian patients with cerebrovascular disease</i> Funding for a Research Fellow (Dr K Kain)	£99,141
June 1995- May 1998	<b>Medical Research Council (ROPA)</b> <i>Control of expression of the angiotensinogen gene and its linkage to hypertension and cerebrovascular disease.</i> Funding for a Post-Doctoral Research Fellow (Dr TS Futers)	£127,166
Sept 1995- Aug 1996	<b>British Heart Foundation (PG\95071)</b> <i>Characterisation of a novel promoter polymorphism in the angiotensin converting enzyme gene and its relation to coronary artery disease.</i> Funding for a Clinical Scientist (Dr A Carter)	£29,504
Aug 1995- July 1997	<b>British Heart Foundation (FS\95031)</b> <i>Cardiovascular risk factors in the first-degree relatives of young patients with cerebrovascular disease.</i> Funding for a Junior Research Fellow (Dr A Lansbury)	£58,432
Sept 1994- Aug 1996	<b>British Heart Foundation (FS\94040)</b> <i>Polymorphisms of candidate genes in relation to coronary artery disease.</i> Funding for Junior Research Fellow (Dr N Ossei-Gerning)	£63,982
Sept 1994- Aug 1995	<b>National Heart Research Fund</b> <i>The role of the angiotensin converting enzyme gene in the pathogenesis of coronary artery disease in ethnic groups.</i> Funding for Post-Doctoral Research Fellow (Dr C Foy)	£29,150
Apr 1994- Apr 1997	<b>The Stroke Association (2/94)</b> <i>The role of coagulation and fibrinolysis in the pathogenesis of recurrent stroke.</i>	£85,423
Apr 1993 -Mar 1995	<b>British Heart Foundation (FS\93008)</b> <i>Polymorphisms of the plasminogen activator inhibitor-1 gene and clustering of cardiovascular risk factors in type 2 diabetic patients and their first-degree relatives.</i> Funding for Junior Research Fellow (Dr M Mansfield)	£57,931

Apr 1993- Apr 1996	<b>The Stroke Association (2/93)</b> <i>Polymorphisms of the angiotensin converting enzyme and plasminogen activator inhibitor-1 genes and risk of stroke.</i> Funding for a Research Fellow (Dr A Catto)	£119,783
Feb 1993	<b>Eli Lilly &amp; Co Ltd</b> Lilly Diabetes Research Grant	£3,500
Nov 1992	<b>British Diabetic Association Small Project Grant</b> <i>Polymorphisms of the plasminogen activator inhibitor-1 gene and clustering of cardiovascular risk factors in type 2 diabetic patients and their first-degree relatives.</i>	£4,270
Apr 1990- Mar 1994	<b>Sir Halley Stewart Trust</b> <i>The effects of advanced glycosylation end products on fibrinolysis in diabetes mellitus</i> Funding to support a technician (Ms L McCormack)	£50,000
1989	<b>Sir Samuel Scott of Yews Trust</b>	£2,000
1989	<b>Garfield Weston Trust</b>	£30,000

#### Grants from Local Sources:

Aug 2000- July 2002	<b>NHS Executive Northern &amp; Yorkshire Research Training Fellowship Award</b> <i>Cardiovascular risk factor clustering in the first degree relatives of subjects with peripheral vascular disease.</i> Fellowship for Dr Duncan Parry	£78,334
Apr 2000- Mar 2002	<b>Leeds Teaching Hospital Special Trustees (ST00/22)</b> <i>The molecular genetics of vascular disorders</i>	£53,020
Apr 1999- Mar 2001	<b>Leeds Teaching Hospitals Special Trustees (ST99/32)</b> <i>The rapid and efficient identification of novel candidate polymorphisms using transgenomic wave DNA fragment analysis system.</i>	£61,000
Apr 1999- Mar 2001	<b>Leeds Teaching Hospitals Arnold Tunstall Fellowship (AT99/01)</b> <i>A family study of haemostatic risk factors with determination of genetic, metabolic and environmental contribution.</i> Funding for a Research Fellow (Dr M Freeman)	£83,575
Apr 1998- Mar 2000	<b>Leeds Teaching Hospitals Special Trustees (ST98/14)</b> <i>The role of factor XIII in vascular disorders.</i>	£21,686
July 1997	<b>University of Leeds Special Equipment Fund</b> <i>Donation to buy -85° Freezer and 2 x centrifuges.</i>	£16,194

Sept 1997- Aug 1998	<b>Leeds Teaching Hospitals Special Trustees (ST97/07)</b> <i>Polymorphisms of the fibrinogen and platelet IIb/IIIa gene in relation to fibrinogen levels and coronary artery disease.</i> Funding for a Research Assistant	£33,126
Apr 1996- Mar 1998	<b>Leeds Teaching Hospitals Special Trustees (ST96/08)</b> <i>Cardiovascular risk factors in the first degree relatives of young patients with cerebrovascular disease.</i> Funding for a Research Nurse	£30,144
Jan 1996	<b>University of Leeds Special Equipment Fund</b> <i>To purchase ACL 300R Coagulation Analyser.</i>	£8,000
Apr 1995	<b>University of Leeds Academic Development Fund</b> <i>Advances in molecular biology research.</i>	£13,745
Apr 1994- Mar 1997	<b>Leeds Teaching Hospitals Special Trustees (ST94/8)</b> <i>The role of coagulation and fibrinolysis in the pathogenesis of recurrent stroke.</i> Funding for a technician	£46,404
Oct 1992- Sept 1993	<b>Locally Organised Research Scheme (LT41) (LGI Trustees)</b> <i>A study of the value of urinary urokinase as a marker of diabetic nephropathy.</i>	£9,040
Oct 1992- Sept 1995	<b>Locally Organised Research Scheme (LT48) (LGI Trustees)</b> <i>Risk stratification and monitoring of diabetic retinopathy using retinal assessments and retinal function tests.</i>	£58,991
Oct 1991- Sept 1992	<b>LGI Special Trustees (ST2)</b> <i>Cardiac muscle hypertrophy in insulin growth factor-1 and growth hormone.</i>	£27,000
Sept 1991- Aug 1995	<b>LGI Special Trustees (LW249)</b> <i>New molecular approach in viral aetiology of diabetes.</i>	£55,000
1990	<b>Local British Diabetic Association</b>	£2,000

### **Financial Support from the Pharmaceutical Industry:**

2002-	<b>Novartis Pharmaceuticals</b> (co-investigator with Dr Andrew Catto) <i>Navigator: A Study using Nateglinide and Valsartan in Patients with Impaired Glucose Tolerance</i>	£45,000
-------	--	---------

2002-	<b>Aventis Pharma</b> <i>AtLantus: A multicentre, multinational, randomised open label study to establish the optimal method for initiating the maintaining Lantus (insulin glargine) therapy based on a comparison of two treatment algorithms to determine optimal metabolic outcomes, safety and satisfaction in subjects with type II diabetes mellitus.</i>	£20,000
Mar 1999- Mar 2006	<b>Bayer Pharmaceuticals</b> <i>Lipids in Diabetes Study - A multicentre, randomised placebo-controlled, double-blind prospective balanced two-by-two factorial design of Cerivastatin 0.4 ml and fenofibrate 200 mg in patients with type 2 diabetes mellitus and without clinical evidence of cardiovascular disease.</i>	£40,000
July 1997- June 2001	<b>Bristol Myers Squibb</b> <i>The Collaborative Study Group Trial: The effects of irbesartan on morbidity and mortality in hypertensive patients with type II diabetes and diabetic nephropathy (CV131-048).</i>	£20,000
July 2000- present	<b>Janssen-Cilag Ltd</b> (co-investigator with Dr John Wales, Leeds) <i>A multicentre, randomised, double-blind, placebo-controlled, parallel group, one-year study of the efficacy and safety of topiramate in the treatment of obese type 2 diabetic subjects treated with metformin. (TOP-INT-34).</i>	£60,000
May 1999- June 2000	<b>SmithKline Beecham Pharmaceuticals (147)</b> <i>A multicentre double blind placebo-controlled, parallel group, comparative study to evaluate the efficacy, safety and tolerability of rosiglitazone (BRL 49653) with concomitant oral therapy with sulphonylurea when administered to patients with type 2 diabetes and who are of Indo-Asian ethnic origin living within the UK.</i>	£100,000
Jan 1997 - present	<b>SmithKline Beecham Pharmaceuticals (009)</b> <i>A multicentre open label extension study to assess the long term safety tolerability and efficacy of BRL 49653C when administered to patients with NIDDM.</i>	£5,720 so far
Aug 1996- Feb 1998	<b>SmithKline Beecham Pharmaceuticals (015)</b> <i>A multicentre double blind placebo controlled parallel group comparative study to evaluate the efficacy safety and tolerability of BRL 49653C with concurrent sulphonylurea therapy when administered to patients with NIDDM.</i>	£28,940
Jan 1995- Jan 1997	<b>Sandoz Pharmaceuticals</b> <i>Placebo controlled study of XU62-320 in patients with type 2</i>	£65,000

*diabetes mellitus and hyperlipidaemia: effects on coagulation and fibrinolysis*

June 1994- Jan 1999	<b>Lipha Pharmaceuticals</b> <i>Fibrinolysis in impaired glucose tolerance. Early Diabetes Intervention Trial.</i>	£32,000
	<b>Lipha Pharmaceuticals</b> <i>Metformin/Factor VII study.</i>	£12,600
Oct 1994- June 1995	<b>Eli Lilly &amp; Co Ltd</b> <i>Lispro (LY275585) v human soluble insulin in patients on multiple insulin injection regimens who inject before meals.</i>	£13,000
May 1994	<b>Shield Diagnostics</b>	£10,000
Jan 1994- Jan 1996	<b>Sandoz Pharmaceuticals</b> <i>Placebo controlled study of the lipid lowering activity of XU63-320 in patients with type 1 diabetes mellitus.</i>	£12,000
Aug 1993- Aug 1995	<b>Parke-Davis Pharmaceuticals</b> <i>A double blind placebo controlled parallel group study of Lopid (gemfibrozil) in dyslipidaemic non-insulin-dependent diabetics under good glycaemic control.</i>	£7,500
1991	<b>Lipha Pharmaceuticals</b>	£65,000
1990	<b>Lipha Pharmaceuticals</b>	£3,500
1990	<b>Novo Nordisk Pharmaceuticals</b>	£5,000

**Director of the Leeds Institute for Genetics Health and Therapeutics (LIGHT),and  
Head of the Academic Unit of Molecular Vascular Medicine  
School of Medicine, University of Leeds**

I was one of the main drivers for the development of the LIGHT laboratories, which are currently under construction on the site bordered by the Worseley Building, the Clarendon Wing and the power station. This biomedical facility incorporates elements of Biological Sciences and the Academic Units of Molecular Epidemiology (Wild) and Molecular Vascular Medicine (Grant) from Medicine. A total of £10m was raised from SRIF and the University to support this development which is on schedule to commence research in October 2004. The LIGHT laboratories will be part of the overarching LIGHT which will consist of Molecular Epidemiology, Molecular Vascular Medicine and Cardiology. I have been appointed as Director of LIGHT from Feb 2004 with academic responsibility for ~250 staff.

As Research Director for the School of Medicine (Oct 2000-Mar 2004) I was Chairman of the School's Research Committee and a member of the Executive Board. I had overall responsibility for the School's submission for the Research Assessment Exercise in April 2001 and was lead for Unit of Assessment 3 for which we received a 4 rating.

In my position as Professor of Medicine and Honorary Consultant Physician in the University of Leeds and ULTH Trust, I spend approximately 33% of my time on clinical activities and most of the remainder on research and administration. The research component includes the role of Head of the Academic Unit of Molecular Vascular Medicine, the laboratories of which are situated in the Martin Wing, Leeds General Infirmary. The Unit is currently funded by The Stroke Association, The British Heart Foundation, the National Heart Research Fund, Diabetes UK, and The Medical Research Council and currently consists of around 35 medical and scientific staff, technicians, research nurses and MD/PhD students. The research interest of the unit is in the genetic and environmental determinants of fibrin structure/function. Initially we concentrated on developing large gene banks of pertinent populations in the fields of vascular disease. Over the last 3 years the work of the unit has moved towards understanding protein structure function in thrombosis. Laboratory techniques available include cell culture, standard and real time PCR, WAVE technology, gel shift analysis, HPLC, surface plasmon resonance, confocal microscopy and mass spectrometry. Results from our work has been published in *The Lancet*, *Blood*, *Circulation*, *Journal of Biological Chemistry*, *Diabetes*, *Arteriosclerosis*, *Thrombosis and Vascular Biology*, *Stroke*, and *Thrombosis and Haemostasis*.

## **TEACHING**

- Examiner for the United Examining Board (1996-present).
- Examiner for the Royal College of Ophthalmologists (1999-present).
- Examiner for Final MBChB [Leeds].
- Internal and External examiner for Postgraduate Degrees.
- Undergraduate and Postgraduate bedside teaching.
- Lecturer in diabetes and general medicine.

## **ADMINISTRATION**

### **Local (NHS/University) Committees**

- Director of The Leeds Institute of Genetics Health and Therapeutics (Feb 2004-)
- Research Director, School of Medicine, University of Leeds (October 2000-Mar 2004).
- Member of the Research Committee, School of Medicine, University of Leeds (2000-present).
- Member of the Executive Committee, School of Medicine, University of Leeds (October 2000-present).
- Member of the Medicine, Dentistry, Psychology & Health Faculty Research Committee (formerly the Management Board, School of Medicine), University of Leeds (October 2000-present).
- Member of the Leeds Teaching Hospitals Trust Research & Development Committee.
- Committee Member for Regional Appointing Committees.
- Member of the Northern & Yorkshire Regional Working Party in Diabetes and Endocrinology (1993-present).
- Member of the Northern & Yorkshire Regional Training Committee in Diabetes and Endocrinology (1993-present).
- Member of the Leeds FHSA Diabetes Advisory Group.
- Postgraduate Tutor for the Research School of Medicine, University of Leeds (1995-98).
- Member of the Management Group, Northern & Yorkshire Clinical Trials & Research Unit.
- Committee Member, Committee on Personal Chairs, University of Leeds (1997-2000).

### **National Committees**

- Royal College of Physicians Committee on Academic Medicine (2003-present)
- Advisory Board, Medical Research Council (Sept 2002-06).
- Fellowships Committee, British Heart Foundation (July 1997-2002).

- International Society for Thrombosis & Haemostasis Birmingham 2003 planning Committee.
- Research Committee, British Diabetic Association (1998-2001).
- Medical & Scientific Committee, British Diabetic Association (1996-1999).
- Secretary and Committee Member, British Society for Haemostasis and Thrombosis, (1995-1997).

### **International Committees**

- Member of the Scientific Organising Committee, XVIIth International Congress on Fibrinolysis and Proteolysis, Melbourne Australia March 2004.
- Chairman, Standardisation Scientific Subcommittee for Predictive Variables of Cardiovascular Disease. International Society for Thrombosis and Haemostasis (November 2003-present).
- Committee Member of the European Society for Clinical Investigation (Jan 2000-present).
- Member of the European Thrombosis Research Organisation

### **Editorial Boards**

- Editor-in-Chief, Diabetes & Vascular Disease Research (2003-present).
- Editorial Board member, Journal of Diabetes and Vascular Disease (2001-present).
- Editorial Board member, Journal of Biotechnology in Healthcare (1994-present).

## **SUPERVISION OF HIGHER DEGREES**

### **Degrees Awarded – PhD**

#### **Dr Christopher P Gale**

PhD February 2004

The development of a knockout glyoxalase gene 1 mouse model for the investigation of the functional significance of glyoxalase 1 in atherosclerosis

University of Leeds

#### **Amany Abd El-Meguid Atwa**

PhD July 2003

Effect of factor XIII val34leu polymorphism on interaction of platelets with fibrin clot.

University of Leeds

#### **Toyin Akinbola**

PhD March 2003

The role of coagulation factor X gene in the pathogenesis of vascular disease

University of Leeds

#### **Nantarat Komanasin**

PhD July 2001

Functional analysis of the B-subunit of factor XIII

University of Leeds

#### **Michael H Wilson**

PhD July 2001

Polymorphisms in glutathione S-transferase genes and the risk of vascular disease

University of Leeds

#### **Barry I Hudson**

PhD September 2000

Identification and functional characterization of the receptor for advanced glycation end-products (RAGE) gene polymorphisms

University of Leeds

+

#### **Gillian I Rice**

PhD September 1999

The molecular biology of vascular disease

University of Leeds

#### **Andrew J Catto**

PhD March 1999

Genetic polymorphisms and the risk of stroke

University of Leeds

#### **Lynn J McCormack**

PhD August 1998

Genetic and environmental factors involved in thrombin generation and suppression of fibrinolysis in relation to diabetes mellitus  
University of Leeds

**Sally Bannan**

PhD April 1998

Inflammatory and haemostatic responses to cardiopulmonary bypass and vascular disease  
University of Leeds

**Angela M Carter**

PhD March 1998

Polymorphisms of fibrinogen and platelet glycoprotein genes: Gene-environment interactions and vascular risk  
University of Leeds

**Degrees Awarded – MD**

**Clair M Sullivan**

MD November 2003

Characterisation of the proposed regulatory region of the ENRAGE gene and the contribution of RAGE polymorphisms to insulin resistance  
University of Leeds

**Paul A Sainsbury**

MD April 2003

A study of novel polymorphisms within the promoter region of the Factor XIII gene, the codon 46 C-T genotype and their relationship to established risk factors for and manifestations of ischaemic heart disease  
University of Leeds

**Kirti Kain**

MD June 2002

Genetic and environmental determinants of cardiovascular risk factors in South Asian patients with cerebrovascular disease and their first-degree relatives  
University of Leeds

**Juliette R Coore**

MD April 2001

Investigation of the genetics of plasminogen activator inhibitor-2 in vascular disease  
University of Leeds

**Alastair J Lansbury**

MD March 2001

Cardiovascular risk factors in the first degree relatives of young patients with cerebrovascular disease.  
University of Leeds

**Michael W Mansfield**

D.M. 1998

University of Oxford

**Nicholas Ossei-Gerning**

MD 1999

Polymorphisms of candidate genes in relation to coronary artery disease  
University of London

**Stephen CL Gough**

M.D. 1996

Fibrinolysis, coagulation and cardiac muscle dysfunction in type 2 diabetes mellitus.  
University of Leeds

**Degrees Awarded – Other**

**Daniella M Heywood**

MPhil February 2001

Molecular genetics of blood coagulation in human vascular disease.  
University of Leeds

**MD Students Currently under Supervision**

**Dr Jonathan M Blaxill**

Functional characterisation of polymorphisms in the tissue plasminogen activator gene promoter and relationship to myocardial infarction  
1999-2003 British Heart Foundation Junior Research Fellowship

**Dr Mark S Freeman**

Genetic and Environmental contribution to plasma haemostatic factors: a family study  
1999-2001 Leeds General Infirmary Special Trustees Arnold Tunstall Fellowship

**Dr Joseph D Mills**

Cardiovascular risk factor clustering in the first-degree relatives of subjects with multivessel coronary artery disease  
1998-2002 British Heart Foundation Junior Research Fellowship

**Dr Duncan J Parry**

Cardiovascular risk factor clustering in the male first degree relatives of male subjects with intermittent claudication  
2001-2003 Yorkshire Region Research Training Fellowship

**Dr Usha K Prasad**

C/EBPa polymorphisms and heritability of insulin resistance and haemostasis  
2002-2005 Wellcome Entry Level Training Fellowship

**Dr Darren P Warner**

The role of factor XIIIVal34Leu in myocardial infarction in male Asian subjects: A case control study  
1998-2002

**Dr Julian P Winter**

DNA damage, atheroma and myocardial infarction  
2001-2003

**PhD Students Currently under Supervision**

**Ms Claire E Bennett**

Functional characterisation of polymorphisms in the tissue plasminogen activator gene promoter and relationship to myocardial infarction  
2001-2004

**Ms Jacqueline A Bostock**

CCAAT/enhancer binding protein b genetic variants and gene regulation: implications for haemostasis and thrombosis  
2000-2004 British Heart Foundation Studentship

**Mr Paul A Cordell**

Characterisation of the genetic regulation and allelic variation of the glyoxalase II gene: implications for diabetic vascular disease  
2000-2003 University of Leeds Mary & Alice Scholarship

**Dr Madhava P Dissanayake**

Identification of factor XIIIa subunit residues involved in B subunit binding  
2002-2005 British Heart Foundation Clinical PhD Studentship

**Ms Sarah J Dolling**

Characterisation of the transcriptional regulation of genetic variants of the receptor for advanced glycation end-products (RAGE)  
2001-2004 British Heart Foundation Studentship

**Dr Emma J Dunn**

Assessment of the genetic influence, and the effect of glycation on the structure and function of fibrinogen  
2002-2005 Wellcome Trust Entry Level Fellowship and Diabetes UK Fellowship

**Ms Amy Jones**

Molecular characterisation of the aminopeptidase P gene promoter  
2002-2005 British Heart Foundation Studentship

**Ms Panagiota Karatza**

Hepatocyte nuclear factor 1 $\alpha$ : its role in insulin resistance and coagulation  
2002-2005 European Foundation for the Study of Diabetes & Servier Laboratories

**Dr Bernard BC Lim**

Analysis of the effects of a common coding polymorphism in the A $\alpha$ B $\beta$  chains of fibrinogen on fibrin structure and function  
2000-2003 British Heart Foundation Clinical Studentship

**Ms Sarah M Mackenzie**

The role of FXIII A-subunit in fibrin formation  
2001-2004 British Heart Foundation Studentship

**Ms Katie E Payne**

b3 integrin gene polymorphisms, gene regulation and vascular risk  
2000-2003 British Heart Foundation Studentship

**Dr Nicholas D Quinn**

The factor XIII B subunit gene: isolation and functional characterisation of the promoter region and the role of allelic variants in cardiovascular disease  
1998-2002 British Heart Foundation Clinical Studentship

**Ms Kristina F Standeven**

Molecular interactions between fibrinogen and factor XIII: effects of Aa Thr312Ala, advanced glycation end-product formation and metformin on the binding, activation and cross-linking reactions  
1999-2004 British Heart Foundation

## **MEMBERSHIP OF LEARNED SOCIETIES**

- Founding Member, International Society for Diabetes & Vascular Disease
- American Heart Association
- American Diabetes Association (No: 842357)
- Atherosclerosis Discussion Group
- Anglo-French Medical Society (No: 356)
- Association of Physicians
- British Society of Haemostasis and Thrombosis
- Diabetes UK (formerly British Diabetes Association) (No: 8306168)
- European Association for the Study of Diabetes (No: 843940)
- European Tissue Culture Society
- European Society for Clinical Investigation (No: 7121598)
- International Society for Thrombosis and Haemostasis (No: 1381)
- Medical Research Society

## **AWARDS**

- Wellcome Travelling Award 1982
- XIth International Society of Thrombosis and Haemostasis Congress Award 1987

## **COURSES ATTENDED**

- Postgraduate Diabetes Workshop, April 11-15th, 1986 Nice, France.
- Management Development for Doctors, Northern & Yorkshire Regional Health Authority 1994-1995.

## NATIONAL AND INTERNATIONAL INVITED LECTURES

- “*Atherothrombosis: Therapeutic targets: Haemostatic Factors*” The Cardiovascular Forum, Vence, France, June 2004
- “*Insulin resistance – an atherothrombotic syndrome*”. Annual European ACTOS Symposia, (sponsored by Takeda). Malta, May 2004.
- “*Insulin resistance – an atherothrombotic syndrome*”. Research Seminars, University of Leicester, UK, May 2004
- “*Do genetic variants of HNF-1 alpha explain the genetic pleiotropy between insulin resistance and coagulation?*” Research Programme on Vascular Complications of Type 2 Diabetes, Paris, France, April 2004.
- International Academic Workshop on Risks and Prevention of Type 2 Diabetes. Mantova, Italy, April 2004.
- Clinical Science Symposia, British Society for Haematology Annual Scientific Meeting, Cardiff, UK, April 2004.
- “*Metabolic disorders associated with type 2 diabetes mellitus*”. San Francisco, USA, March 2004.
- “*Genetic and environmental determinants of fibrin structure/function*“. XVIIth International Congress on Fibrinolysis and Proteolysis, Melbourne, Australia, March 2004.
- “*Inflammation and the Vasculature*” Actos Global Leadership Conference, New York, March 2004 (sponsored by Takeda Europe R&D).
- “*Is type 2 diabetes an inflammatory disease?*”. Type 2 Diabetes: A fresh look at old Problems (sponsored by Takeda). Estepona, Spain, 27<sup>th</sup> February 2004.
- “*Insulin Resistance – an atherothrombotic syndrome*”. 2<sup>nd</sup> Insulin Resistance Symposium, West Yorkshire, February 2004.
- “*The Metabolic Syndrome: Relationship to Diabetes*”. Type 2 diabetes, The Metabolic Syndrome and Obesity: Evolving the Paradigms”. Roundtable meeting. Duke Clinical Research Institute, Washington, USA, January 2004.
- “*Type2 diabetes and cardiovascular disease – what is the common soil?*”. Lilly Diabetes Advisory Board meeting, London, November 2003.
- “*The interface between cardiology and diabetes*”. Postgraduate Meeting, Wolfson Conference Centre, Hammersmith Hospital, London, November 2003.
- “*Coagulopathy and diabetes – beyond aspirin*” Association of British Clinical Diabetologists Annual Meeting, London, November 2003.
- “*Impaired Fibrinolysis in Patients with Diabetes*” 3<sup>rd</sup> Annual Diabetes Summit, Florida, USA, November 2003.
- “*Fibrinogen gamma chain splice variant ( $\gamma$ ) alters fibrin structure and function: A mechanism for increased thrombotic risk*”. American Heart Association, Florida, USA, November 2003.
- *Traditional Risk Factors: Emerging Risk Factors* (sponsored by GlaxoSmithKline). London Conrad Hotel, London, October 2003.

- *'Variations in genes regulating fibrin cross-linking (FXIII)'* BAS/BSHT Annual meeting Cambridge, UK, September 2003.
- *'Genetics of atherothrombotic disorders: a clinical perspective'*. XIX International Society for Thrombosis & Haemostasis. State of the Art Lecture, Birmingham, UK, July 2003.
- *'Thrombosis and vascular occlusion'* North of England Gastroenterology Society Spring Meeting, Elland, West Yorkshire, UK June 2003.
- *'Pharmacogenetics'* Atherothrombosis 2003 - European Society of Cardiology Working Group on Thrombosis, Florence, Italy, June 2003.
- *'Mechanisms of platelet aggregation in diabetes mellitus'* MEDCON (Europe) Diabetes Interventional Working Group, Paris, France, May 2003.
- *'Complications of Diabetes'* Juvenile Diabetes Research Fund Open Meeting, Leeds, UK, May 2003.
- 2<sup>nd</sup> European ACTOS Symposium, Budapest, Hungary, May 2003.
- Career Development Workshop, University of Leeds, Leeds, UK, April 2003.
- *'Prevention of type 2 diabetes and its progression from inflammation to infarction'* 9<sup>th</sup> Barts One Day International Symposium. London, UK, April 2003.
- Diabetes Education Forum Conference, Seville, Spain, April 2003.
- *'Diabetes associated cardiovascular risk and glitazones'* GlaxoSmithKline GP meeting, Bradford, UK, February 2003.
- *'Diabetes and Fibrinolysis'* American Heart Association, Chicago, November 2002.
- *'Insulin resistance, gene environment interactions and cardiovascular risk'* 17<sup>th</sup> International Congress on Thrombosis, Bologna, Italy, October 2002.
- *'Insulin resistance, gene environment interactions and cardiovascular risk'* Postgraduate Lecture Glasgow, Scotland, October 2002.
- *'Diabetes as a Cardiovascular Disease'* 8 Day Lecture Series, Japan, July 2002.
- *'The Genetics of Macrovascular Disease'*, American Diabetes Association, San Francisco, USA, June 2002.
- *'Diabetes as a Cardiovascular Disease'* Postgraduate Lecture, Ninewells Hospital, Dundee, May 2002.
- *'Diabetes as a Cardiovascular Disease'* Postgraduate Lecture, Guy's Hospital, London, May 2002.
- *'Diabetes as a Cardiovascular Disease'* RCP Training Day in Diabetes & Endocrinology, Strayside Education Centre, Harrogate, UK, March 2002.
- *'Ethnicity and Cardiovascular Risk'*. GP Target Workshop, Weetwood Hall, Leeds, February 2002.
- *'Genetics of clot formation and embolisation'*. 3<sup>rd</sup> Thrombosis Symposium, Paris, October 2001.
- *'Insulin resistance and beta cell dysfunction – one side or equal therapeutic targets? Their role in the development of cardiovascular complications'* Merck Lipla Symposium EASD, Glasgow, UK, September 2001.

- *'Twin studies to evaluate the genetics of haemostatic variables'*. SSC Meeting, International Society for Haemostasis and Thrombosis XVIII Congress, Paris, France July 2001.
- *'Diabetes, haemostasis and vascular risk'*. International Society for Haemostasis and Thrombosis, XVIII Congress, Paris, France July 2001.
- Penn State University, Philadelphia, June 2001.
- Hammersmith Hospital, London, UK, June 2001.
- *'Genes of the haemostatic pathways: role in arterial thrombosis'*. 14<sup>th</sup> Congress of the Spanish Society of Atherosclerosis & 35<sup>th</sup> Annual Meeting of the European Society for Clinical Investigation. Barcelona, Spain, May 2001.
- *'The role of metabolic alterations in haemostasis and in thrombotic disease'*. Thromboembolic Disease: from Genetics to Bedside, Murcia, Spain, April 2001.
- *'Factor XIII and vascular disorders'*. Hammersmith Hospital, London, UK, February 2001.
- *'Insulin resistance: an atherothrombotic syndrome'*. Insulin Resistance – Origins, Consequences and Treatment, New Forest, UK, February 2001
- Departmental Seminars, Manchester Royal Infirmary, February 2001.
- *'Update on Molecular Risk Factors for Arterial Thrombosis: Pathological polymorphisms of coagulation factors'* European Society of Cardiology, Amsterdam, August 2000.
- *'Genetics of Coagulation Factor XIII in Relation to Protection Against Thrombotic Disorders including Myocardial Infarction'*, International Symposium on Cardiovascular Disorders, Positano, Italy, June 2000.
- *'Role of Factor XIII Polymorphisms in Thrombosis and Bleeding'* First North Sea Conference on Hemostasis and Thrombosis, Maastricht, The Netherlands, June 2000.
- *'Genetic Abnormalities and Polymorphisms of Coagulation and Fibrinolytic Factors'*. XV<sup>th</sup> International Congress on Fibrinolysis and Thrombosis, Japan, June 2000.
- *'Vascular Biology and Thrombosis: Role of Factor XII in Bleeding and Thrombotic Occlusion'*. 5<sup>th</sup> European Haematology Association meeting, Birmingham, UK, June 2000.
- *'Diabetes and Vascular Disease'* First Liverpool Symposium on Type 2 Diabetes, Liverpool, UK, May 2000.
- *'The Molecular Genetics of Haemostasis in Relation to Arterial Thrombosis'* Portugal, May 1999.
- *'The Genetics of Factor XIII and Vascular Disorders'* European Thrombosis Research Organisation, Leiden, March 2000.
- *'Gene Mutations and Thrombosis'* Workshop. Milan, Italy, February 2000.
- *'The Molecular Genetics of Hemostasis and Vascular Risk'* Haemophilia Comprehensive Care Centre Evening Lectures, University of Liverpool, October 1999.

- *'Gene: environment interactions and Cardiovascular Disease'* British Heart Foundation AGM London, UK, September 1999.
- *'FXIII Val34Leu and Vascular Disease'* ISTH SSC meeting Washington, USA, August 1999.
- *'The Genetics of Thrombosis, Insulin Resistance and Vascular Risk'* Gastroenterology Research Group Lunchtime Seminars, University of Liverpool, UK, July 1999.
- *'Prothrombotic States as a Challenge for Pharmacotherapy: Genetic Predisposition'* European Society of Cardiology, Barcelona, Spain, Aug/Sept 1999.
- *'Insulin Resistance, Genetics and Vascular Risk'* International Postgraduate Course "Diabetes 1999", Santiago, Chile, July 1999.
- *'Metformin and Cardiovascular Risk: Treatment of Type 2 Diabetes after the UKPDS'* International Postgraduate Course "Diabetes 1999", Santiago, Chile, July 1999.
- *'Weight Loss or Metformin for Obese Type 2 Diabetics?'* International Postgraduate Course "Diabetes 1999", Santiago, Chile, July 1999.
- *'Metformin and Prevention'* International Postgraduate Course "Diabetes 1999", Santiago, Chile, July 1999.
- *'Genetics of Cardiovascular Disease'* Round Table meeting. Lansdowne, Virginia, USA, April 1999.
- *'Genetics of Vascular Disease'* Northern Vascular Biology Meeting, Manchester Royal Infirmary, March 1999.
- *'Genetics of coagulation factor XIII and atherothrombotic disorders'* Medicine Departmental Seminars Manchester Royal Infirmary, February 1999.
- *'Pathological polymorphisms in the blood and vessel wall'* European Society of Cardiology, Vienna, Austria, August 1998.
- *'Factor XIII and PAI-1'* European Society of Cardiology, Vienna, Austria, August 1998
- *'The molecular genetics of coronary heart disease'* Regional Cardiology Audit Meeting, Wakefield, UK, July 1998.
- *'Factor XIII and Vascular Disorders'* ISTH/ETRO SSC Meeting Ljubljana, Slovenia, June 1998.
- *'How to Recognise Critical Factors'* Fibrinolysis & Proteolysis Workshop, Leiden, The Netherlands, April 1998.
- *'Insulin Resistance, Gene-Environment Interactions and Vascular Risk'* Postgraduate Meeting, Institute of Clinical Science, Exeter, February 1998.
- *'Genetics of haemostasis and cardiovascular disease'* Postgraduate Course, Rigshospitalet, Copenhagen, Denmark, December 1997.
- *'Insulin resistance and vascular disease: gene environment interactions and thrombotic risk'* Molecular Epidemiology Group One Day Meeting, ICRF, Lincoln's Inn Fields, London, November 1997.
- *'Fibrinolysis - Genetics Aspects'* Satellite Symposium: Haemostatic Variables in Atherothrombosis: Prediction and Prevention. Marseilles, France, October 1997.

- *'Molecular Genetics of Cardiovascular Disease'* ETRO Advanced Teaching Course. Heviz, Hungary, October 1997.
- *'Factor XIII Val34Leu, Insulin Resistance and Vascular Risk'* Shering. Berlin, Germany, September 1997.
- *'Platelet Glycoprotein IIb/IIIa Polymorphisms'* European Society of Cardiology: Working Group on Thrombosis and Platelets, Stockholm, Sweden, August 1997.
- *'Factor XIII in Vascular Disorders'* ETRO Working Party on Factor XII, Eger, Hungary, May 1997.
- *'The Molecular Genetics of Cardiovascular Disease'* Morriston Hospital, Swansea, September 1996.
- *'Adhesion Molecules and Endothelial Cell Markers in Diabetes Mellitus'* British Diabetic Association Symposium, Exeter, September 1996.
- *'Polymorphisms of Coagulation/Fibrinolysis Genes: Gene-Environment Interactions and Vascular Risk'* ETRO/ISSFAL Meeting, Maastricht, The Netherlands, July 1996.
- *'Polymorphisms of the PAI-1 Gene and Cerebrovascular Disease'* XIIIth International Congress on Fibrinolysis and Thrombolysis, Barcelona, June 1996.
- *'Clustering of Cardiovascular Risk Factors Associated with Insulin Resistance'* Royal Society of Medicine, London, May 1996.
- *'Effects of Metformin on Cardiovascular Risk'* Santiago, Chile, March 1996.
- *'Mechanisms of Metformin Action'* Guayaquil, Ecuador, March 1996
- *'Mechanisms of Metformin Action'* Quito, Ecuador, March 1996
- *'Clinical Use of Metformin'* Guayaquil, Ecuador, March 1996.
- *'Clinical Use of Metformin'* Quito, Ecuador, March 1996.
- *'Diabetes: Classification and Pathophysiology'* Bogota, Colombia, March 1996.
- *'Metformin as Monotherapy and With Sulphonylureas'* Bogota, Colombia, March 1996.
- *'Metformin as a Monotherapy and in Combination with a Sulphonylurea in Non-Insulin Dependent Diabetes Mellitus'* 9th Latin American Diabetes Association, Iguassa Falls, Brazil, November 1995.
- *'Metformin in Combination with Insulin Therapy'* 9th Latin American Diabetes Association, Iguassu Falls, Brazil, November 1995.
- *'Metformin, Blood Pressure and other Cardiovascular Risk Factors'* 9th Latin American Diabetes Association, Iguassu Falls, Brazil, November 1995.
- *'Metabolic Syndrome in Diabetes Mellitus: Relevance to Vascular Disease'* Postgraduate Centre, Ninewells Hospital, Dundee, November 1995.
- *'Polymorphisms of RA Systems in Coronary Artery Disease'*. British Heart Foundation Conference, London, November 1995.
- *'How to Measure Thrombotic Risk Using Genetic Polymorphism Haemostatic Factors: Factor V and PAI-1'* European Society of Cardiology, Amsterdam, August 1995.

- *'The Relation Between Genetic Polymorphism and Levels of Haemostatic Factors: What Now, What Next?'* European Thrombosis Research Organization Working Party, Santa Maria Imbaro, Italy, April 1995.
- *'Insulin resistance and Vascular Disease'* Atherosclerosis Discussion Group, Oxford, March 1995.
- *'Metabolic Syndrome in Diabetes Mellitus - Relevance to Vascular Disease'* British Society for Haemostasis and Thrombosis, St Andrews, March 1995.
- *'Metformin, Blood Pressure and Other Cardiovascular Risk Factors'* Glucophage International Symposium: NIDDM Prevention and Treatment, Heidelberg, Germany, September 1994.
- *'Insulin Resistance and Fibrinolysis'* The Rayne Institute, University College Hospital, London, June 1994.
- *'Physiological Role of Vasopressin on Haemostasis'* International Scientific Meeting of Haematologists from South-East Asian Countries, Medan, Indonesia, December 1993.
- *'Molecular Biology of Plasminogen Activator Inhibitor'* International Scientific Meeting of Haematologists from South-East Asian Countries, Medan, Indonesia, December 1993.
- *'Pachyderms, Pimas and Pains in the Chest'* Postgraduate Day Keynote Lecture, The General Infirmary, Leeds, April 1993.
- *'Fibrinolytic Therapy in Thrombosis'* International Meeting on Physiology of Haemostasis and Thrombosis, Porto, Portugal, November 1992.
- *'The Regulation of Haemostasis'* Workshop on Desmopressin, Lucca, Italy, April 1992.
- *'Coagulopathy in Diabetes Mellitus'* Advanced Postgraduate Course in Diabetes, University of Newcastle upon Tyne, January 1992.
- *'Fibrinolysis in Diabetes and the Relationship with Vascular Disease'* Diabetes Workshop, St Andrews, October 1991.
- *'Fibrinolysis in Health and Disease'* European Thrombosis Research Organisation, 4<sup>th</sup> Advanced Teaching Course, Leeds 1991.
- *'Hormonal Control of Fibrinolysis'* Atherosclerosis Discussion Group, Oxford University, April 1988.
- *'Treatment of Deep Vein Thrombosis and Pulmonary Embolism: Can we Improve on Anticoagulants?'* Leeds University, November 1987.
- *'The Physiological Role of Vasopressin in the Regulation of Haemostasis in Man'*. National Institute of Biological Standards and Control, August 1987.

## PUBLICATIONS

### ORIGINAL ARTICLES:

- |  | <b>Impact<br/>Factor</b> |
|--|--------------------------|
| 1. Cordell PA, Futers TS, <b>Grant PJ</b> , Pease RJ. The human hydroxyacylglutathione hydrolase (HAGH) gene encodes both cytosolic and mitochondrial forms of glyoxalase II. <i>Journal of Biological Chemistry</i> , 2004; in press.   |                          |
| 2. Dunn EJ, Ariens RA, de Lane M, Snieder H, Turney JH, Spector TD, <b>Grant PJ</b> . Genetics of fibrin clot structure: a twin study. <i>Blood</i> , 2004, 103 (5):1735-1740.   |                          |
| 3. Standeven KF, <b>Grant PJ</b> , Carter AM, Scheiner T, Weisel JW, Ariens RAS. Functional Analysis of the Fibrinogen A $\alpha$ Thr312Ala polymorphism: Effects on fibrin structure and function. <i>Circulation</i> 2003; 107:2326-2330.  | 10.52                    |
| 4. Philippou H, Rance J, Myles T, Hall SW, Ariens RA, <b>Grant PJ</b> , Leung L, Lane DA. Roles of low specificity and cofactor interaction sites on thrombin during factor XIII activation: competition for cofactor sites on thrombin determines its fate. <i>J Biol Chem</i> 2003; 278:32020-6. | 6.696                    |
| 5. De Lange M, Snieder H, Ariens RAS, Andrew T, <b>Grant PJ</b> , Spector DT. The relation between insulin resistance and hemostasis: Pleiotropic genes and common environment. <i>Twin Research</i> 2003; 6 (2) 6: 152-161.   |                          |
| 6. Barnett AH, <b>Grant PJ</b> , Hitman GA, Mather H, Pawa M, Robertson L, Trelfa A. Indo-Asian Trial Investigators: Rosiglitazone in type 2 diabetes mellitus: an evaluation in British Indo-Asian patients. <i>Diabetic Medicine</i> 2003; 20: 38793.  |                          |
| 7. Kain K, Catto AJ, <b>Grant PJ</b> . Associations between insulin resistance and thrombotic risk factors in high-risk South Asian subjects. <i>Diabetic Medicine</i> 2003; 20: 651-655.  | 2.68                     |
| 8. Carter AM, Anagnostopoulou K, Mansfield MW, <b>Grant PJ</b> . Soluble P-selectin levels, P-selectin polymorphisms and cardiovascular disease. <i>Journal of Thrombosis and Haemostasis</i> . 2003;1: 1718-1723.   | 4.91                     |
| 9. Lim BCB, Ariens RAS, Carter AM, Weisel JW, <b>Grant PJ</b> . The genetic regulation of fibrin structure/function: Evidence for complex gene:environment interactions that modulate vascular risk. <i>Lancet</i> 2003; 361: 1424-1431  | 13.25                    |
| 10. Pettersson-Fernholm K, Forsblom C, Hudson BI, Perola M, <b>Grant PJ</b> , Groop P-H for the FinnDiane Study Group. The functional -374 T/A RAGE gene polymorphism is associated with proteinuria and cardiovascular disease in type 1 diabetic patients. <i>Diabetes</i> 2003; 52: 891-894.    | 7.72                     |
| 11. Wilson MH, <b>Grant PJ</b> , Kain K, Warner DP, Wild CP. Association between the risk of coronary artery disease in South Asians and a deletion polymorphism in glutathione S transferase M1. <i>Biomarkers</i> , 2003; 8: 43-50.  | 1.12                     |

12. Freeman MS, Mansfield MW, Barrett JH, **Grant PJ**. Insulin resistance: an atherothrombotic syndrome. The Leeds Family Study. *Thrombosis and Haemostasis* 2003; 89: 161-168. 4.91
13. Winter JP, Gong YY, Grant PJ, Wild CP. Glutathione peroxidase 1 genotype is associated with an increased risk of coronary artery disease. *Coronary Artery Disease* 2003; 14: 149-153. 1.098
14. Lansbury AJ, **Grant PJ**, Catto AJ. Atherothrombotic risk factors in subjects with a family history of stroke. *Cerebrovascular Diseases* 2002; 14: 153-60. 2.95
15. Ariëns RAS, de Lange M, Snider H, Spector TD, **Grant PJ**. Activation of coagulation and fibrinolytic system and thrombotic tendency. *Lancet* 2002; 360: 802 (invited rebuttal letter). 13.25
16. Mills JD, Ariens RAS, Mansfield MW, **Grant PJ**. Altered fibrin clot structure in the healthy relatives of patients with premature coronary artery disease. *Circulation* 2002; 106: 1938-1942. 9.76
17. Kain K, Catto AJ, Young J, Bamford J, Bavington J, **Grant PJ**. Coagulation factor VII activity, Arg/Gln353 polymorphism and features of insulin resistance in first degree relatives of south Asian patients with stroke. *Thrombosis and Haemostasis* 2002; 88: 954-960. 4.91
18. Kain K, Catto AJ, **Grant PJ**. Clustering of thrombotic factors with insulin resistance in South Asian patients with ischemic stroke. *Thrombosis and Haemostasis* 2002; 88: 950-953. 4.91
19. Kain K, Catto AJ, Young JB, Bamford JM, Bavington J, **Grant PJ**. Determinants of plasminogen activator inhibitor-1 in South Asians with ischaemic stroke. *Cerebrovascular Diseases* 2002; 14: 77-83. 2.95
20. van Hylckama Vlieg A, Komnasin N, Ariëns RAS, Poort SR, **Grant PJ**, Bertina RM, Rosendaal FR. Factor XIII Val34Leu polymorphism, factor XIII antigen levels and activity and the risk of deep venous thrombosis. *British Journal of Haematology* 2002; 119: 169-175. 3.07
21. Kohler HP, Ariëns RA, Catto AJ, Carter AM, Miller GJ, Cooper JA, Mansfield MW, Standeven KF, **Grant PJ**. Factor XIII A-subunit concentration predicts outcome in stroke subjects and vascular outcome in healthy middle-aged men. *British Journal of Haematology* 2002; 118: 825-32. 2.82
22. Hofmann MA, Drury S, Hudson BI, Gleason MR, Qu W, Lu Y, Lalla E, Chitnis S, Monteiro J, Stickland MH, Bucciarelli LG, Moser B, Parisien M, Moxley G, Itescu S, **Grant PJ**, Gregersen PK, Stern DM, Schmidt AM. RAGE and arthritis: the G82S polymorphism amplifies the inflammatory response. *Genes and Immunity* 2002; 3: 123-35. 3.22
23. Kain K, Blaxill JM, Catto AJ, **Grant PJ**, Carter AM. Increased fibrinogen levels in South Asians versus Whites in the United Kingdom are not explained by common polymorphisms. *American Journal of Epidemiology* 2002; 156: 174-179. 3.87

24. Herlihy OM, Barrow BA, **Grant PJ**, Levy JC. Hyperglycaemic siblings of type 2 (non-insulin-dependent) diabetic patients have increased PAI-1, central obesity and insulin resistance compared with their paired normoglycaemic sibling. *Diabetologia* 2002; 45: 635-641. 5.72
25. Hayat M, Ariëns RAS, Moayyedi P, **Grant PJ**, O'Mahony S. Coagulation factor XIII and markers of thrombin generation and fibrinolysis in patients with inflammatory bowel disease. *European Journal of Gastroenterology & Hepatology* 2002; 14: 249-256.
26. Ariëns RAS, de Lange M, Snieder H, Boothby M, Spector TD, **Grant PJ**. Activation markers of coagulation and fibrinolysis in twins: heritability of the pre-thrombotic state. *Lancet* 2002; 359: 667-671. 10.23
27. Mills J, Mansfield MW, **Grant PJ**. Tissue plasminogen activator, fibrin D-Dimer and insulin resistance in the relatives of patients with premature coronary artery disease. *Arteriosclerosis, Thrombosis & Vascular Biology* 2002; 22: 704-709. 5.11
28. Freeman MS, Mansfield MW, Barrett JH, **Grant PJ**. Genetic contribution to circulating levels of haemostatic factors in healthy families with effects of known genetic polymorphisms on heritability. *Arteriosclerosis, Thrombosis & Vascular Biology* 2002; 22(3): 506-10. 5.11
29. Freeman MS, Mansfield MW, Barrett J, **Grant PJ**. Heritability of features of the insulin resistance syndrome in a community-based study of healthy families. *Diabetic Medicine* 2002; 19: 994-999.
30. Kain K, Catto AJ, Young J, Bamford J, Bavington J, **Grant PJ**. Increased fibrinogen, von Willebrand factor and tissue plasminogen activator levels in insulin resistant South Asian patients with ischemic stroke. *Atherosclerosis* 2002; 163: 371-376. 3.39
31. Mills JD, Mansfield MW, **Grant PJ**. Factor XIII – circulating levels and the Val34Leu polymorphism in the healthy male relatives of patients with severe coronary artery disease. *Thrombosis & Haemostasis* 2002; 87: 409-414. 4.37
32. Mills JD, Mansfield MW, **Grant PJ**. Elevated fibrinogen in the healthy male relatives of patients with severe, premature coronary artery disease. *European Heart Journal* 2002; 23: 1276-1281. 3.84
33. Hassan A, Lansbury A, Catto AJ, Guthrie A, Spencer J, Craven C, **Grant PJ**, Bamford JM. Angiotensin converting enzyme insertion/deletion genotype is associated with leukoaraiosis in lacunar syndromes. *Journal of Neurology, Neurosurgery, and Psychiatry* 2002; 72: 343-346. 2.85
34. Standeven KF, Ariëns RAS, Whitaker P, Ashcroft AE, Weisel JW, **Grant PJ**. The effect of dimethylbiguanide on thrombin activity, FXIII activation, fibrin polymerisation and fibrin clot formation. *Diabetes* 2002; 51: 189-197. 7.72
35. Hudson BI, Stickland MH, **Grant PJ**, Futers TS. Characterisation of allelic and nucleotide variation between the RAGE gene on chromosome 6 and a homologous pseudogene sequence to its 5' regulatory region on chromosome 3: implications for 7.72

- polymorphic studies in diabetes. *Diabetes* 2001; 50: 2646-51 (rapid publication).
36. Hudson BI, Stickland MH, Futers TS, **Grant PJ**. Study of the -429 T/C and -374 T/A receptor for advanced glycation end products promoter polymorphisms in diabetic and nondiabetic subjects with macrovascular disease. *Diabetes Care* 2001; 24; 2004 (letter). 4.99
  37. Lewis EJ et al **for the Collaborative Study Group**. Renoprotective effects of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. *New England Journal of Medicine*, 2001; 345: 851-60. 29.52
  38. Hudson BI, Stickland MH, Futers TS, **Grant PJ**. Effects of novel polymorphisms in the RAGE gene on transcriptional regulation and their association with diabetic retinopathy. *Diabetes* 2001; 50: 1505-1511. 7.72
  39. Warner D, Mansfield M, **Grant PJ**. Coagulation factor XIII levels in UK Asian subjects with type 2 diabetes mellitus and coronary artery disease. *Thrombosis and Haemostasis* 2001; 86: 1117-1118 (letter). 4.37
  40. Rice GI, Futers TS, **Grant PJ**. Identification of novel polymorphisms within the Protein Z gene, haplotype distribution and linkage analysis. *Thrombosis and Haemostasis* 2001; 85:1123-1124 (letter). 4.37
  41. Kain K, Catto AJ, Young JB, Bamford JM, Bavington J, **Grant PJ**. Insulin resistance and elevated levels of tissue plasminogen activator in the first-degree relatives of South Asian patients with ischaemic cerebrovascular disease. *Stroke* 2001; 32: 1069-1073. 4.32
  42. Kain K, Catto AJ, Carter AM, Young J, Bamford J, Bavington J, **Grant PJ**. Decreased fibrinolytic potential in South Asian women with ischaemic cerebrovascular disease. *British Journal of Haematology* 2001; 114: 155-161. 3.07
  43. Costa M, **Grant PJ**, Rice GI, Futers TS, Medcalf RL. Human endothelial cell-derived nuclear proteins that recognise polymorphic DNA elements in the von Willebrand Factor gene promoter include YY1. *Thrombosis and Haemostasis* 2001; 86: 672-679. 4.37
  44. Amini-Nekoo A, Futers TS, Moia M, Mannucci PM, **Grant PJ**, Ariëns RAS. Analysis of the tissue factor pathway inhibitor gene and antigen levels in relation to venous thrombosis. *British Journal of Haematology* 2001; 113: 537-543. 3.07
  45. Catto AJ, Ariëns RAS, **Grant PJ**. Relationship between FXIIIVal34Leu and Factor V Leiden in patients with venous thrombosis (invited response). *Blood* 2001; 97: 1894-1896 (letter). 8.98
  46. Kohler HP, Ariëns RAS, Mansfield MW, Whitaker P, **Grant PJ**. Factor XIII activity and antigen levels in patients with coronary artery disease. *Thrombosis and Haemostasis* 2001; 85: 569-570 (letter). 4.37
  47. Warner D, Mansfield MW, **Grant PJ**. Coagulation factor XIII and cardiovascular disease in UK Asian patients undergoing coronary angiography. *Thrombosis and Haemostasis* 2001; 85: 408-411. 4.37

48. Kain K, Catto AJ, **Grant PJ**. Impaired fibrinolysis and elevated fibrinogen levels in healthy South Asian and white subjects. *Atherosclerosis* 2001; 156: 457-461. 3.39
49. de Lange M, Snieder H, Ariëns RAS, Spector TD, **Grant PJ**. The genetics of haemostasis. A twin study. *Lancet* 2001; 357: 101-5. 10.23
50. Ariëns RAS, Philippou H, Nagaswami C, Weisel JW, Lane DA, **Grant PJ**. The factor XIII Val34Leu polymorphism accelerates thrombin activation of factor XIII and affects crosslinked fibrin structure. *Blood* 2000, 96: 988-995. 8.98
51. Carter AM, Catto AJ, Kohler HP, Ariëns RAS, Stickland MH, **Grant PJ**.  $\alpha$ -Fibrinogen Thr312Ala polymorphism and venous thromboembolism. *Blood* 2000; 96: 1177-1179. 8.98
52. Warner DP, Catto AJ, Kunz G, Ireland H, **Grant PJ**, Lane DA. The thrombomodulin gene mutation G<sup>127</sup>-A (Ala25Thr) and cerebrovascular disease. *Cerebrovascular Diseases* 2000; 10: 359-363. 1.62
53. Ashcroft AE, **Grant PJ**, Ariëns RAS. A study of human coagulation factor XIII A-subunit by electrospray ionisation mass spectrometry. *Rapid Communications in Mass Spectrometry* 2000; 14: 1607-1611. 2.6
54. Catto A, McCormack LJ, Mansfield MW, Carter AM, Bamford J, Robinson P, **Grant PJ**. Apolipoprotein E polymorphism in cerebrovascular disease. *Acta Neurologica Scandinavica* 2000; 101: 399-404. 0.90
55. Mansfield MW, Kohler HP, Ariens RAS, McCormack L, **Grant PJ**. Circulating levels of coagulation factor XIII in subjects with type 2 diabetes mellitus and their first degree relatives. *Diabetes Care* 2000; 23: 703-705 (letter). 3.32
56. Wilson MH, **Grant PJ**, Hardie LJ, Wild CP. Glutathione S-transferase M1 null genotype is associated with a decreased risk of myocardial infarction. *FASEB Journal* 2000; 14: 791-796. 14.63
57. Gale EAM for the UK Trial Group. A randomised, controlled trial comparing insulin lispro with human soluble insulin in patients with type 1 diabetes on intensified insulin therapy. *Diabetic Medicine* 2000; 17: 209-214. 1.60
58. Carter AM, Catto AJ, Bamford JM, **Grant PJ**. The association of the platelet glycoprotein IIb HPA-3 polymorphism with survival following acute ischaemic stroke. *Stroke* 1999; 30: 2606-2611. 4.32
59. Kohler HP, Mansfield MW, Clark PS, **Grant PJ**. Interaction between insulin resistance and factor XIII Val34Leu in patients with coronary artery disease. *Thrombosis and Haemostasis* 1999; 82: 1202-3 (letter). 4.58
60. Kohler HP, Futers TS, **Grant PJ**. FXII (46C→T) polymorphism and in vivo generation of FXII activity. *Thrombosis and Haemostasis* 1999; 81: 745-747. 4.58
61. Ariens RAS, Kohler HP, Mansfield MW, **Grant PJ**. Subunit antigen and activity levels of blood coagulation factor XIII in healthy individuals: relation to gender, age, smoking and hypertension. *Arteriosclerosis, Thrombosis and Vascular Biology* 5.32

- 1999; 19: 2012-2016.
62. Carter A, Catto AJ, **Grant PJ**. Association of the  $\alpha$ -fibrinogen Thr312Ala polymorphism with post-stroke mortality in subjects with atrial fibrillation. *Circulation* 1999; 99: 2423-2426. 9.76
  63. Kohler HP, Futers TS, **Grant PJ**. Prevalence of three common polymorphisms in the a-subunit gene of factor XIII in patients with coronary artery disease: Association with FXIII activity and antigen levels. *Thrombosis and Haemostasis* 1999; 81: 511-515. 4.58
  64. Catto AJ, Kohler HP, Coore J, Mansfield MW, Stickland MH, **Grant PJ**. Association of a common polymorphism in the factor XIII gene with venous thrombosis. *Blood* 1999; 3: 906-908. 9.51
  65. Rice GI, Foy CA, **Grant PJ**. Angiotensin converting enzyme and angiotensin II type 1 receptor gene polymorphisms and risk of ischaemic heart disease *Cardiovascular Research* 1999; 41: 746-753. 2.88
  66. Wartiovaara U, Perola M, Mikkola H, Totterman K, Savolainen V, Penttila A, **Grant PJ**, Tikkanen MJ, Vartiainen E, Karhunen PJ, Peltonen L, Palotie A. Association of FXIII Val34Leu with decreased risk of myocardial infarction in Finnish males. *Atherosclerosis* 1999; 142: 295-300. 2.88
  67. Salooja N, Catto A, Carter A, Tuddenham EGD, **Grant PJ**. Methylene tetrahydrofolate reductase C677T genotype and stroke. *Clinical and Laboratory Haematology* 1998; 20: 357-361. 0.36
  68. Bailey CJ, **Grant PJ**. The UK Prospective Diabetes Study. *Lancet* 1998; 352: 1932 (letter). 16.14
  69. Kohler HP, **Grant PJ**. Clustering of haemostatic risk factors with FXIIIVal34Leu in patients with myocardial infarction. *Thrombosis and Haemostasis* 1998; 80: 862 (letter). 4.58
  70. Rice GI, **Grant PJ**. FVIII coagulant activity and antigen in subjects with ischaemic heart disease. *Thrombosis and Haemostasis* 1998; 80: 757-762. 4.58
  71. McCormack L, Semple JI, Stickland MH, Barrett JH, **Grant PJ**. The effect of number of days in culture and plasminogen activator inhibitor-1 (PAI-1) promoter region 4G/5G genotype on PAI-1 antigen release by cultured human umbilical vein endothelial cells. *Thrombosis Research* 1998; 92: 199-206. 1.46
  72. Carter AM, Catto AJ, **Grant PJ**. Determinants of tPA antigen and associations with coronary artery disease and acute cerebrovascular disease. *Thrombosis and Haemostasis* 1998; 80: 632-636. 4.58
  73. Mansfield, MW, Catto AJ, Carter AM, **Grant PJ**. Fibrinolytic measurements in type 2 diabetes patients with acute cerebral infarction. *Diabetic Medicine* 1998; 15: 953-957. 1.60
  74. McCormack L, Kain K, Catto AJ, Kohler HP, Stickland MH, **Grant PJ**. Prevalence of FXIII V34L in populations with different cardiovascular risk. *Thrombosis and*

- Haemostasis* 1998; 80: 523-4 (letter).
75. Kohler HP, Ariens RAS, Whitaker P, **Grant PJ**. A common coding polymorphism in the FXIII a-subunit gene (FXIIIVal34Leu) affects cross-linking activity. *Thrombosis and Haemostasis* 1998; 80: 704 (letter). 4.58
  76. Carter AM, **Grant PJ**. Platelet P1<sup>A</sup> polymorphism, myocardial infarction and extent of coronary artery disease. *Circulation* 1998; 98: 826-827 (letter). 9.76
  77. Carter AM, Catto AJ, Bamford JM, **Grant PJ**. Platelet GP IIIa P1<sup>A</sup> and GP Ib variable number tandem repeat polymorphisms and markers of platelet activation in acute stroke. *Arteriosclerosis, Thrombosis and Vascular Biology* 1998; 18: 1124-1131. 5.32
  78. Kohler HP, Stickland MH, Ossei-Gerning N, Carter A, Mikkola H, **Grant PJ**. Association of a common polymorphism in the factor XIII gene with myocardial infarction. *Thrombosis and Haemostasis* 1998; 79: 8-13. 4.58
  79. Catto AJ, Kohler HP, Bannan S, Stickland M, Carter A, **Grant PJ**. Factor XIII Val 34 Leu : A novel association with primary intracerebral haemorrhage. *Stroke* 1998; 29: 813-816. 4.32
  80. Kohler HP, Carter AM, Stickland MH, **Grant PJ**. Levels of activated FXII in survivors of myocardial infarction – association with circulating risk factors and extent of coronary artery disease. *Thrombosis and Haemostasis* 1998; 79: 14-18. 4.58
  81. Carter AM, Mansfield MW, **Grant PJ**. Polymorphisms of platelet glycoproteins in relation to macrovascular disease in type 2 diabetes mellitus. *Diabetic Medicine* 1998; 15: 315-319. 1.60
  82. Ossei-Gerning N, Wilson IJ, **Grant PJ**. Sex differences in coagulation and fibrinolysis in subjects with coronary artery disease. *Thrombosis and Haemostasis* 1998; 79: 736-740. 4.58
  83. Nagi DK, Foy CA, Mohamed-Ali V, Yudkin JS, **Grant PJ**, Knowler WC. Angiotensin-1 converting enzyme (ACE) gene polymorphism, plasma ACE levels, and their association with the metabolic syndrome and electrocardiographic coronary artery disease in Pima Indians. *Metabolism* 1998; 47: 622-626. 1.68
  84. Bannan S, Mansfield MW, **Grant PJ**. Soluble vascular cell adhesion molecule-1 and E-selectin levels in relation to vascular risk factors and to E-selectin genotype in the first degree relatives of NIDDM patients and in NIDDM patients. *Diabetologia* 1998; 41: 460-466. 5.35
  85. **Grant PJ**. Metformin reduces circulating factor VII concentrations in patients with type 2 diabetes mellitus. *Thrombosis and Haemostasis* 1998; 80: 209 (letter). 4.58
  86. Hudson BI, Stickland MH, **Grant PJ**. Identification of polymorphisms in the receptor for advanced glycation end products (RAGE) gene: prevalence in type 2 diabetes and ethnic groups. *Diabetes* 1998; 47: 1155-1157. 8.68
  87. Moayyedi P, Carter AM, Catto AJ, Heppell RM, **Grant PJ**, Axon ATR. Validation of a rapid whole blood test for the diagnosis of *Helicobacter pylori* infection. *British*

*Medical Journal* 1997; 314: 119.

88. Mansfield MW, Stickland MH, **Grant PJ**. PAI-1 concentrations in first-degree relatives of patients with non-insulin-dependent diabetes: metabolic and genetic associations. *Thrombosis and Haemostasis* 1997; 77: 357-361. 4.58
89. Ossei-Gerning N, Mansfield MW, Stickland MH, Wilson IJ, **Grant PJ**. Plasminogen activator inhibitor-1 promoter 4G/5G genotype and plasma levels in relation to a history of myocardial infarction in patients characterised by coronary angiography. *Arteriosclerosis, Thrombosis and Vascular Biology* 1997; 17: 33-37. 5.32
90. **Grant PJ**. Plasminogen activator inhibitor-1 gene and myocardial infarction. *Circulation* 1997; 96: 17(letter). 9.76
91. Foy CA, **Grant PJ**. PCR-RFLP detection of PAI-2 gene variants: prevalence in ethnic groups and relationship to disease in patients undergoing coronary angiography. *Thrombosis and Haemostasis* 1997; 77: 955-958. 4.58
92. Heywood DM, Carter AM, Catto AJ, Bamford JM, **Grant PJ**. Polymorphisms of the Factor VII gene and circulating FVII:C levels in relation to acute cerebrovascular disease and post-stroke mortality. *Stroke* 1997; 28: 816-821. 4.32
93. Catto AJ, Carter AM, Stickland M, Bamford JM, Davies JA, **Grant PJ**. Plasminogen activator inhibitor-1 (PAI-1) 4G/5G Promoter polymorphism and levels in subjects with cerebrovascular disease. *Thrombosis and Haemostasis* 1997; 77: 730-734. 4.58
94. Carter A, Catto AJ, Bamford JM, **Grant PJ**. Gender specific associations of the fibrinogen B $\beta$  448 polymorphism, fibrinogen levels and acute cerebrovascular disease. *Arteriosclerosis, Thrombosis and Vascular Biology* 1997; 17: 589-594. 5.32
95. Ossei-Gerning N, Mansfield MW, Stickland MH, **Grant PJ**. Insulin receptor substrate-1 gene polymorphism and cardiovascular risk in non-insulin dependent diabetes mellitus and patients undergoing coronary angiography. *Clinical and Laboratory Haematology* 1997; 19: 123-128. 0.36
96. Catto AJ, Carter AM, Barrett JH, Bamford J, Rice P, **Grant PJ**. von Willebrand factor and factor VIII:C in acute cerebrovascular disease: relationship to stroke subtype and mortality. *Thrombosis and Haemostasis* 1997; 77: 1104-1108. 4.58
97. Kohler HP, Boothby M, McCormack L, Knowler WC, **Grant PJ**. Incidence of Arg506  $\rightarrow$ Gln mutation (Factor V Leiden) in Pima Indians. *Thrombosis and Haemostasis* 1997; 78: 961-2 (letter). 4.58
98. Nagi DK, McCormack LJ, Mohamed-Ali V, Yudkin JS, Knowler WC, **Grant PJ**. Diabetic retinopathy, promoter (4G/5G) polymorphism of PAI-1 gene, PAI-1 activity in Pima Indians with non-insulin dependent diabetes. *Diabetes Care* 1997; 20: 1304-1309. 3.32
99. Foy CA, Rice GI, Ossei-Gerning N, Mansfield MW, **Grant PJ**. Angiotensin converting enzyme (ACE) gene polymorphisms in patients characterised by coronary angiography. *Human Genetics* 1997; 100: 420-425. 2.66

100. Carter AM, Ossei-Gerning, Wilson IJ, **Grant PJ**. Association of the platelet P1<sup>A</sup> polymorphism of glycoprotein IIb/IIIa and the fibrinogen B $\beta$  448 polymorphism with myocardial infarction and extent of coronary artery disease. *Circulation* 1997; 96: 1424-1431. 9.76
101. Ossei-Gerning N, Moayyedi P, Smith S, Braunholtz D, Wilson IJ, Axon ATR, **Grant PJ**. Helicobacter pylori infection is related to atheroma in patients undergoing angiography. *Cardiovascular Research* 1997; 35: 120-4. 2.88
102. Trigwell P, **Grant PJ**, House A. Motivation and glycaemic control in diabetes mellitus. *Journal of Psychosomatic Research* 1997; 43: 307-315.
103. Rice GI, Ossei-Gerning N, Stickland MH, **Grant PJ**. The paraoxonase Gln-Arg 192 polymorphism in subjects with ischaemic heart disease. *Coronary Artery Disease* 1997; 8 (11/12): 677-682. 0.65
104. Lansbury AJ, Catto AJ, Carter AM, Bamford JM, **Grant PJ**. The paraoxonase Glutamine/Arginine polymorphism and cerebrovascular disease. *Cerebrovascular Diseases* 1997; 7: 353-356. 1.62
105. Mansfield MW, Heywood DM, **Grant PJ**. Sex differences in coagulation and fibrinolysis in white subjects with non-insulin-dependent diabetes mellitus. *Arteriosclerosis, Thrombosis and Vascular Biology* 1996; 16: 160-164. 5.32
106. Heywood D, Mansfield MW, **Grant PJ**. Factor VII gene polymorphisms, factor VII:C levels and features of insulin resistance in non-insulin-dependent diabetes mellitus: A link with vascular risk. *Thrombosis and Haemostasis* 1996; 75:401-406. 4.58
107. Catto A, Carter AM, Barrett JH, Stickland MH, Bamford J, Davies JA, **Grant PJ**. Angiotensin-converting enzyme insertion/deletion polymorphism and cerebrovascular disease. *Stroke* 1996; 27: 435-440. 4.32
108. Catto A, Carter A, **Grant PJ**. Factor V gene mutation and completed stroke. *Stroke* 1996; 27: 573 (Letter). 4.32
109. Foy CA, McCormack L, Knowler WC, Barrett JH, Catto A, **Grant PJ**. The angiotensin-I converting enzyme (ACE) gene I/D polymorphism and ACE levels in Pima Indians. *Journal of Medical Genetics* 1996; 33: 336-337. 2.39
110. Carter AM, Moayyedi P, Catto A, Heppell RM, Axon ATR, **Grant PJ**. The influence of *Helicobacter pylori* status on circulating levels of coagulation factors fibrinogen, von Willebrand factor, factor VII and factor VIII. *Helicobacter* 1996; 1(1): 65-69.
111. Heywood DM, Mansfield MW, **Grant PJ**. Levels of von Willebrand factor, insulin resistance syndrome and a common vWF gene polymorphism in (type 2) diabetes mellitus. *Diabetic Medicine* 1996; 13: 720-725. 1.60
112. Carter AM, Mansfield MW, Stickland MH, **Grant PJ**.  $\beta$ -Fibrinogen gene -455 G/A polymorphism and fibrinogen levels: risk factors for coronary artery disease in subjects with NIDDM. *Diabetes Care* 1996; 19: 1265-1268. 3.32

113. Dexter SPL, Griffith JP, **Grant PJ**, McMahon MJ. Activation of coagulation and fibrinolysis in open and laparoscopic cholecystectomy. *Surgical Endoscopy* 1996; 10: 1069-1074. 2.273
114. Heywood DM, Ossei-Gerning N, **Grant PJ**. Association of factor VII:C levels with environmental and genetic factors in patients with ischaemic heart disease and coronary atheroma, characterised by angiography. *Thrombosis and Haemostasis* 1996; 76: 161-165. 4.58
115. Mansfield MW, Heywood DM, **Grant PJ**. Circulating levels of factor VII, fibrinogen and von Willebrand factor and features of insulin resistance in first degree relatives of patients with NIDDM. *Circulation* 1996; 94: 2171-2176. 9.76
116. McCormack LJ, Nagi DK, Stickland MH, Mansfield MW, Mohamed-Ali V, Yudkin JS, Knowler WC, **Grant PJ**. Promoter (4G/5G) plasminogen activator inhibitor-1 genotype in Pima Indians: relationship to plasminogen activator inhibitor-1 levels and features of the insulin resistance syndrome. *Diabetologia* 1996; 39: 1512-1518. 5.35
117. Carter AM, Ossei-Gerning, **Grant PJ**. Platelet glycoprotein IIIa P1<sup>A</sup> polymorphism in young men with myocardial infarction. *Lancet* 1996; 348: 485-6 (letter). 16.14
118. Carter AM, Ossei-Gerning N, **Grant PJ**. Platelet glycoprotein IIIa polymorphism and myocardial infarction. *New England Journal of Medicine* 1996; 335: 1072-1073 (letter). 27.77
119. **Grant PJ**. The effects of high- and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes mellitus *Diabetes Care* 1996; 19:64-66. 3.32
120. Barrett JH , Foy CA, **Grant PJ**. Commingling analysis of the distribution of a phenotype conditioned on two marker genotypes: application to plasma angiotensin-converting enzyme levels. *Genetic Epidemiology* 1996; 13: 615-625. 1.73
121. Mansfield MW, Stickland MH, **Grant PJ**. Plasminogen activator inhibitor-1 (PAI-1) promoter polymorphism and coronary artery disease in non-insulin-dependent diabetes. *Thrombosis and Haemostasis* 1995; 74: 1032-1034.
122. Gough SCL, Smyllie J, Barker M, Berkin KE, Rice PJS, **Grant PJ**. Diastolic dysfunction is not related to changes in glycaemic control over 6 months in type 2 (non-insulin-dependent) diabetes mellitus. *Acta Diabetologica*, 1995; 32: 110-115.
123. Catto AJ, Carter AM, Ireland H, Bayston TA, Philippou H, Barrett J, Lane DA, **Grant PJ**. Factor V Leiden gene mutation and thrombin generation in relation to the development of acute stroke. *Arteriosclerosis, Thrombosis and Vascular Biology* 1995; 15: 783-785.
124. Ibbotson SH, Catto A, Davies JA, **Grant PJ**. The effect of insulin-induced hypoglycaemia on factor VIII:C concentration and thrombin activity in subjects with type 1 (insulin-dependent) diabetes. *Thrombosis and Haemostasis* 1995; 73: 243-246.
125. Nagi DK, Mansfield MW, Stickland MH, **Grant PJ**. Angiotensin converting

- enzyme (ACE) insertion/deletion (I/D) polymorphism and diabetic retinopathy in subjects with IDDM and NIDDM. *Diabetic Medicine* 1995; 12: 997-1001.
126. Mansfield MW, **Grant PJ**. Fibrinolysis and diabetic retinopathy in NIDDM. *Diabetes Care* 1995; 18: 1577-1581.
  127. Mansfield MW, Stickland MH, **Grant PJ**. Environmental and genetic factors in relation to elevated circulating levels of plasminogen activator inhibitor-1 in Caucasian patients with non-insulin dependent diabetes mellitus. *Thrombosis and Haemostasis* 1995; 74: 842-847.
  128. **Grant PJ**, Stickland MH, Mansfield MW. Insulin receptor substrate-1 gene and cardiovascular risk factors in NIDDM. *Lancet* 1995; 346: 841-842 (letter).
  129. Foy CA, Quirke P, Williams DJ, Lewis FA, **Grant PJ**, Eglin R, Bodansky HJ. A search for candidate viruses in type I diabetic pancreas using the polymerase chain reaction. *Diabetic Medicine* 1994; 11: 564-569.
  130. Mansfield MW, Stickland MH, Carter AM, **Grant PJ**. Polymorphisms of the plasminogen activator inhibitor-1 gene in type 1 and type 2 diabetes, and in patients with diabetic retinopathy. *Thrombosis and Haemostasis* 1994; 71: 731-736.
  131. Gough SCL, McCormack L, Rice PJS, **Grant PJ**. The fibrinolytic response to exercise at diagnosis and after 12 months in patients with type 2 diabetes mellitus. *Fibrinolysis* 1994; 8: 372-377.
  132. Gough SCL, Pullar T, Rice PJS, Zebouni L, **Grant PJ**. The fibrinolytic system and disease activity in rheumatoid arthritis and the effects of prednisolone therapy. *Fibrinolysis* 1993; 7: 97-102.
  133. Prentice CRM, Hampton, KK, **Grant PJ**, Nelson SR, Nieuwenhuizen W, Gaffney PJ. The fibrinolytic response to anocrod therapy: characterization of fibrinogen and fibrin degradation products. *British Journal of Haematology* 1993; 83: 276-281.
  134. McCormack L, Stickland MH, **Grant PJ**. Plasminogen activator inhibitor-1 antigen concentrations during insulin and oral glucose tolerance in obese man. *Fibrinolysis* 1993; 7: 225-228.
  135. Ibbotson SH, Rayner H, Stickland MH, Davies JA, Grant PJ. Thrombin generation and factor VIII:C levels in patients with Type 1 diabetes complicated by nephropathy. *Diabetic Medicine* 1993; 10: 336-340.
  136. Gough SCL, Rice PJS, McCormack L, Chapman C, **Grant PJ**. The relationship between plasminogen activator inhibitor-1 and insulin resistance in newly-diagnosed type 2 diabetes mellitus. *Diabetic Medicine* 1993; 10: 638-642.
  137. Ibbotson SH, Gough SCL, Rice PJS, Davies JA, **Grant PJ**. The effect of short-term exercise on plasma procoagulant activity in patients with type II (non-insulin-dependent) diabetes and healthy volunteers. *Thrombosis Research* 1993; 71: 149-158.
  138. Padayatty SJ, Orme S, Zenobi PD, Stickland MH, Belchetz PE, **Grant PJ**. The effects of insulin-like growth factor-1 on plasminogen activator inhibitor-1 synthesis

- and secretion: Results from in-vitro and in-vivo studies. *Thrombosis and Haemostasis* 1993; 70: 1009-1013.
139. Ibbotson SH, Davies JA, **Grant PJ**. The influence of infusions of 1-desamino-8-D-arginine vasopressin (DDAVP) in vivo on thrombin generation in vitro. *Thrombosis and Haemostasis* 1992; 68: 37-39.
  140. Gough SCL, Smylie J, Sheldon T, Rice PJS, **Grant PJ**. The anatomical distribution of plasma fibrinolytic activity in man during cardiac catheterisation. *Thrombosis and Haemostasis* 1992; 68: 442-447.
  141. Gough SCL, Whitworth S, Rice PJS, **Grant PJ**. The effect of exercise and heart rate on fibrinolytic activity. *Blood Coagulation and Fibrinolysis* 1992; 3: 179-182.
  142. Ibbotson SH, Walmsley D, Davies JA, **Grant PJ**. Generation of thrombin activity in relation to FVIII:C concentrations and vascular complications in type 1 diabetes mellitus. *Diabetologia* 1992; 35: 863-867.
  143. Orme SM, Sebastian JP, Oldroyd B, Stewart SP, **Grant PJ**, Stickland MH, Smith MA, Belchez PB. Comparison of measures of body composition in a trial of low dose growth hormone replacement therapy. *British Journal of Endocrinology* 1992; 2: 63-68.
  144. Ibbotson SH, **Grant PJ**, Kerry R, Findlay VS, Prentice CRM. The influence of 1-desamino-8-d-Arginine vasopressin (DDAVP) in-vivo on the anticoagulant effect of recombinant hirudin (CGP39393) in-vitro. *Thrombosis and Haemostasis* 1991; 65: 64-66.
  145. **Grant PJ**, Stickland MH, Booth NA, Prentice CRM. Metformin causes a reduction in basal and post-venous occlusion levels of plasminogen activator inhibitor-1 in Type 2 diabetic patients. *Diabetic Medicine* 1991; 8: 361-365.
  146. **Grant PJ**, Ruegg M, Medcalf RL. Basal expression and insulin mediated induction of PAI-1 mRNA in Hep G2 cells. *Fibrinolysis* 1991; 5: 81-86.
  147. Hampton KK, **Grant PJ**, Primrose J, Dean HG, Davies JA, Prentice CRM. Haemostatic responses and vasopressin release during colonoscopy in man. *Clinical Science* 1991; 81: 257-260.
  148. Walmsley D, Hampton KK, **Grant PJ**. Contrasting fibrinolytic responses in type 1 (insulin-dependent) and type 2 (non insulin-dependent) diabetes. *Diabetic Medicine* 1991; 8: 954-959.
  149. **Grant PJ**, Hampton KK, Primrose J, Davies JA, Prentice CRM. Vasopressin and haemostatic responses to inguinal hernia repair under local anaesthesia. *Blood Coagulation and Fibrinolysis* 1991; 2: 647-650.
  150. Hampton KK, Esack A, Peatfield RC, **Grant PJ**. Vasopressin release in spontaneous migraine. *Cephalalgia* 1991; 11: 249-250.
  151. **Grant PJ**, Kruihof EKO, Felley CP, Felber JP, Bachmann F. Short-term infusions of insulin, triacylglycerol and glucose do not cause acute increases in plasminogen

- activator inhibitor-1 concentrations in man. *Clinical Science* 1990; 79: 513-516.
152. Hampton KK, **Grant PJ**, Boothby M, Dean HG, Davies JA, Prentice CRM. The effect of modified electroconvulsive therapy on vasopressin release and haemostasis in man. *Blood Coagulation and Fibrinolysis* 1990; 1: 293-297.
  153. Hampton KK, **Grant PJ**, Johnston D, Prentice CRM. Pelvic haemophilic pseudotumour occurring in a patient with mild haemophilia: brief report. *Blood Coagulation and Fibrinolysis* 1990; 1: 747-748.
  154. Peatfield RC, Hampton KK, **Grant PJ**. Plasma vasopressin levels in induced migraine attacks. *Cephalalgia* 1988; 8, 55-57.
  155. Wiles PG, **Grant PJ**, Stickland MH, Dean HG, Wales JK, Davies JA. Regional variation in skin blood flow response to hypoglycaemia in type 1 (insulin dependent) diabetic patients without complications. *Diabetologia* 1988; 31, 98-102.
  156. Jones RG, Grant, PJ, Brown D, Stickland MH, Wiles PG. A rise in the plasma activities of hepatic enzymes is not a common consequence of hypoglycaemia. *Diabetic Medicine* 1988; 5, 253-255.
  157. **Grant PJ**, Stickland MH, Davies JA, Prentice CRM. Effect of controlled hyperglycaemia on factor VIII concentrations in insulin dependent diabetes. *Thrombosis Research* 1988; 50, 157-162.
  158. **Grant PJ**, Stickland MH, Bristow AF, Clark RF, Wales JK. Insulin promotes somatomedin C (IGF-1) release in adult insulin-dependent diabetic patients. *Diabetic Medicine* 1989; 6: 245-248.
  159. **Grant PJ**, Stickland MH, Wiles PG, Gaffney PJ, Davies JA, Prentice CRM. Acute changes in glycaemia control do not promote thrombin generation or fibrin breakdown in insulin dependent diabetes. *Diabetic Medicine* 1998; 5: 867-870.
  160. Hariman H, **Grant PJ**, Hughes JR, Davies JA, Prentice CRM. The effect of physiological concentrations of vasopressin in components of the fibrinolytic pathway. *Thrombosis and Haemostasis* 1989; 61: 298-300.
  161. Wiles PG, Hampton KK, **Grant PJ**, Davies JA, Prentice CRM. Lithium therapy does not prevent the effects of vasopressin on skin microvessels. *Horm Metab Res* 1989; 21: 530-531.
  162. **Grant PJ**, Hampton KK, Mahmoud M, Davies JA, Prentice CRM. Persistent activation of the extrinsic fibrinolytic system with normal intrinsic responses in a patient with gastric carcinoma. *Fibrinolysis* 1990; 4: 41-43.
  163. Johnson EJ, Hariman H, Hampton KK, **Grant PJ**, Davies JA, Prentice CRM. Fibrinolysis during major abdominal surgery. *Fibrinolysis* 1998; 4: 147-151.
  164. Bodansky HJ, Dean BM, **Grant PJ**, McNally J, Schweiger MS, Hambling MH, Bottazzo GF, Wales JK. Does response to rubella virus generate endocrine auto-immunity? *Diabetic Medicine* 1990; 7: 611-614.

165. Wilson J, **Grant PJ**, Davies JA, Boothby M, Gaffney PJ, Prentice CRM. The relationship between plasma vasopressin and changes in coagulation and fibrinolysis during hip surgery. *Thrombosis Research* 1988; 51, 439-445.
166. Price DE, **Grant PJ**, Airey CM, Stickland MH, Kemp J, Wales JK. Red cell sorbitol levels during hyper- and hypo-glycaemic clamp studies in insulin- dependent diabetic patients. *Diabetic Medicine* 1987; 4, 229-232.
167. **Grant PJ**, Wiles PG, Dean HG, Davies JA, Prentice CRM. The physiological effects of vasopressin on haemostasis are not caused by catecholamine release. *Thrombosis Research* 1987; 45, 839-843.
168. **Grant PJ**, Stickland MH, Wiles PG, Davies JA, Wales JK, Prentice CRM. Hormonal control of haemostasis during hypoglycaemia in diabetes mellitus. *Thrombosis and Haemostasis* 1987; 57, 341-344.
169. **Grant PJ**, Hughes JR, Dean HG, Davies JA, Prentice CRM. Vasopressin and catecholamine secretion during apomorphine- induced nausea mediate acute changes in haemostatic function in man. *Clinical Science* 1986; 71: 621-624.
170. Wiles PG, **Grant PJ**, Davies JA. The differential effect of arginine vasopressin on skin blood flow in man. *Clinical Science* 1986; 71: 633-638.
171. Wiles PG, **Grant PJ**, Jones RG, Knibbs AV, Hampton, IFG. Lowered skin blood flow at exhaustion. *Lancet* 1986; ii: 295 (letter).
172. Bodansky HJ, **Grant PJ**, Dean BM, McNally J, Bottazzo GF, Hambling MH, Wales JK. Islet-cell antibodies and insulin autoantibodies in association with common viral infections. *Lancet* 1986; ii, 1352-1353.
173. **Grant PJ**, Tate GM, Williams NS, Davies JA, Prentice CRM. Intra-operative activation of coagulation - a stimulus to thrombosis mediated by vasopressin? *Thrombosis and Haemostasis* 1986; 55: 104-107.
174. Wiles PG, **Grant PJ**, Davies JA. White line sign: indicator of hazards of peripheral vasopressin infusion. *British Medical Journal* 1986; 292: 396.
175. **Grant PJ**, Davies JA, Tate GM, Hughes JR, Prentice CRM. Does hypernatraemia promote thrombosis? *Thrombosis Research* 1985; 40: 393-399.
176. **Grant PJ**, Davies JA, Tate GM, Boothby M, Prentice CRM. Effects of physiological concentrations of vasopressin on haemostatic function in man. *Clinical Science* 1985; 69: 471-476.
177. **Grant PJ**, Barlow E, Miles DW. Plasma C-peptide levels identify insulin-treated diabetic patients suitable for oral therapy. *Diabetic Medicine* 1984; 1: 284-286.

## REVIEW ARTICLES:

1. **Grant PJ.** Beneficial effects of metformin on haemostasis and vascular function in man. *Diabetes & Metabolism* 2003; 29: 6S44-52.
2. **Grant PJ.** The genetics of atherothrombotic disorders – a clinicians view. *Journal of Thrombosis & Haemostasis*, 2003; 7, 1381-90
3. Ariëns RAS, Lai TS, Weisel JW, Greenberg CS, **Grant PJ.** Role of factor XIII in fibrin clot formation and effects of genetic polymorphisms. *Blood* 2002, 100: 743-754.
4. Mills J, **Grant PJ.** Insulin resistance, haemostatic factors and cardiovascular risk. *British Journal of Diabetes and Vascular Disease* 2002; 2: 19-26.
5. Kain, K, Catto AJ, **Grant PJ.** Insulin resistance syndrome in South Asians. *British Journal of Diabetes and Vascular Disease* 2002; 2: 398-402.
6. Carter AM, **Grant PJ.** To lyse or not to lyse: is it genetic? *Italian Heart Journal: Official Journal of the Italian Federation of Cardiology*, 2001; 2(9) 652-5.
7. Kain K, Catto AJ, **Grant PJ.** Epidemiology of cardiovascular risk factors in migrant South Asians (invited review). *Asian Journal of Clinical Cardiology*, 2001; 4: 55-66.
8. Kain K, Catto AJ, **Grant PJ.** The molecular genetics of ischaemic heart disease and ischaemic cerebrovascular disease (invited review). *Asian Journal of Clinical Cardiology*, 2001; 4: 24-35.
9. Winkelmann BR, Hager J, Kraus WE, Merlini P, Keavney B, **Grant PJ**, Muhlestein JB, Granger CB. Genetics of coronary heart disease: Current knowledge and research principles. *American Heart Journal* 2000; 140: 11-26.
10. Kohler HP, **Grant PJ.** Plasminogen activator inhibitor (PAI-1) and coronary artery disease. *New England Journal of Medicine*, 2000, 342: 1792-1801.
11. Lane DA, **Grant PJ.** Role of haemostatic gene sequence polymorphisms in venous and arterial disease. *Blood*, 2000, 95 (5) 1-16.
12. Gale C, **Grant PJ.** Environmental influences and coronary heart disease. *Journal for Primary Care Groups*, 2000.
13. Quinn ND, **Grant PJ.** Coagulation disorders, vascular disease and diabetes. *Current Medical Literature – Vascular Disease*, 2000; 3(4): 1-6.
14. Quinn ND, **Grant PJ.** Insulin resistance, thrombosis and vascular risk in type 2 diabetes mellitus. *Practical Diabetes*, 1999; 16: 255-258.
15. Kohler HP, **Grant PJ.** The role of factor XIII Val34Leu in cardiovascular disease. *Quarterly Journal of Medicine*, 1999; 92: 67-72.

16. **Grant PJ**, Humphries SE. Genetic determinants of arterial thrombosis. *Bailliere's Clinical Haematology*, 1999; 12 (3): 177-204.
17. Foy CA, **Grant PJ**. Genetics and medicine: Genes and the development of vascular disease. *Postgraduate Medical Journal* 1997; 73: 271-278.
18. Catto AJ, **Grant PJ**. Haemostatic and genetic determinants of cerebrovascular disease. (Review). *Current Medical Literature - Stroke Review* 1997; 1: 4-9.
19. Carter A, **Grant PJ**. Vascular homeostasis, adhesion molecules and macrovascular disease in non-insulin-dependent diabetes mellitus. *Diabetic Medicine* 1997; 14: 423-432.
20. **Grant PJ**. Polymorphisms of coagulation/fibrinolysis genes: gene-environment interactions and vascular risk. *Prostaglandins, Leukotrienes and Essential Fatty Acids* 1997; 57: 473-477.
21. Catto AJ, **Grant PJ**. Haemostatic and genetic determinants of cerebrovascular disease. (Review). *Current Medical Literature - Neurology & Neurosurgery* 1997; 3: 3-9.
22. Catto AJ, **Grant PJ**. Haemostatic and genetic determinants of cerebrovascular disease. *Current Medical Literature - Thrombosis* 1996; 6 (3): 63-69
23. **Grant PJ**. The effects of metformin on cardiovascular risk factors. *Diabetes/ Metabolism Reviews* 1995; 11, S43-S50.
24. Catto AC, **Grant PJ**. The role of coagulation and fibrinolysis in cerebrovascular disease. *Blood, Coagulation & Fibrinolysis* 1995; 6: 497-510.
25. **Grant PJ**. Plasminogen activator inhibitor-1 and vascular disease in non-insulin dependent diabetes mellitus. *Current Medical Literature - Diabetes* 1995; 12(3): 67-71.
26. **Grant PJ**. Plasminogen activator inhibitor-1 and vascular disease in non-insulin dependent diabetes mellitus. *Current Medical Literature - Thrombosis* 1995; 5(3): 63-67.
27. **Grant PJ**. Physiology of fibrinolysis and its pharmacological role in the management of coronary artery disease. *Anquivos de Medicina* 1993; vol 7 suppl 8: pp 21-25.
28. **Grant PJ**. The fibrinolytic system in health and disease. *Current Medical Literature - Thrombosis* 1992; 2: 63-68.
29. Gough SCL, **Grant PJ**. The fibrinolytic system in diabetes mellitus. *Diabetic Medicine* 1991; 8: 898-905.
30. **Grant PJ**. Disorders of the fibrinolytic system in diabetes mellitus. *Treating Diabetes* 1991; 34: 8-11.
31. **Grant PJ**. The effects of metformin on the fibrinolytic system in diabetic and non diabetic subjects. *Diabete et Metabolisme* 1991; 17: 168-173.

32. **Grant PJ**, Wiles PG. The role of 8-arginine vasopressin (antidiuretic hormone) in vascular homeostasis. *Vascular Medicine Review* 1991; 2: 15-24.
33. **Grant PJ**. Hormonal regulation of the acute haemostatic response to stress. *Blood Coagulation and Fibrinolysis* 1990; 1: 299-306.
34. **Grant PJ**, Medcalf RL. Hormonal regulation of haemostasis and the molecular biology of the fibrinolytic system. *Clinical Science* 1990; 78: 3-11.
35. **Grant PJ**. Metformin and diabetes - a suitable case for treatment? *Practical Diabetes* 1989; 6(3): 137-138.
36. **Grant PJ**, Prentice CRM. Hemorrhage and Thromboembolic complications associated with surgery. *British Medical Bulletin* 1988; 44(2): 453-474.

#### **EDITORIALS:**

1. **Grant PJ**. Diabetes and cardiovascular disease: the Gordian Knot (Editorial). *British Journal of Diabetes and Vascular Disease* 2002;2(5): 347-348.
2. Gale CP, **Grant PJ**. Atherothrombotic disease and factor XIII: lucky for some? Invited commentary. *European Journal of Clinical Investigation* 2002; 32: 637-640.
3. **Grant PJ**. The Edinburgh Artery Study: Is lytic activity bad for the heart? (Editorial). *European Heart Journal*, 2000; 21: 1566-1567.

#### **CHAPTERS:**

1. **Grant PJ**, Mills JD. Atherothrombotic risk clustering, insulin resistance and cardiovascular disease. In: Hypertension and Diabetes Volume 2. Eds: Lippincott Williams & Wilkins Healthcare, UK, 2003, in press.
2. Ariëns RAS, **Grant PJ**. Hemostasis. In: The Handbook of Diabetes and Cardiovascular Disease. Ed: Marso SP. Remedica Publishing, London, 2003 pp45-68.
3. Greenberg CS, Ariëns RAS, Weisel JW, **Grant PJ**. Biology and disorders of fibrinogen and factor XIII. Blood Principles and Practice of Hematology, Second Edition. Ed: Handlin RI, Lux IV SE, Stossel TP. Lippincott Williams & Wilkins, Philadelphia, USA, 2003 pp 1225-1248.
4. **Grant PJ**, Summers LKM. Diabetes, impaired fibrinolysis and thrombosis. In: Diabetes Mellitus and Cardiovascular Disease. Eds: Marso SP, Stern DM. Lippincott, Williams & Wilkins, Philadelphia, USA, 2003 pp 269-292.
5. **Grant PJ**, Davies JA. Cardiovascular diseases and diabetes. In: Textbook of Diabetes, 3<sup>rd</sup> Edition. Eds: Pickup JC, Williams G. Blackwell Science, UK, 2002 Vol 2: pp 56.1-56.24.

6. Carter AM, **Grant PJ**. Common genetic determinants of coagulation and fibrinolysis. In: Emery & Rimoin's Principles and Practice of Medical Genetics, 4<sup>th</sup> Edition. Eds: Rimoin DL, Connor JM, Pyeritz RE, Korf BR. Churchill Livingstone; London 2002 pp 1327-1341.
7. Carter AM, **Grant PJ**. Vascular complications: the molecular basis of vascular disease. In: Oxford Textbook of Endocrinology. Eds: Wass JAH, Shalet SM, Gale E, Amiel SA. Oxford University Press, Oxford, UK 2002, pp 1755-1764.
8. Ariëns RAS, **Grant PJ**. Factor XIII (protransglutaminase). Laki-Lorand factor; fibrin stabilising factor. In: Encyclopedia of Molecular Medicine, Volume 2. John Wiley & Sons, New York. 2001, Vol 2: pp 1243-1246.
9. **Grant PJ**. Coagulation and fibrinolysis in type 2 diabetes: relationship to microvascular complications. In: Vascular Disease in Diabetes: A report of the Hemovascular Study Group. Ed: Tooke J. Wells Healthcare Communications Ltd, 2001: pp 15-32.
10. Lansbury AJ, **Grant PJ**. Clustering of risk factors, hypertension, diabetes and fibrinolysis. In: Handbook of Hypertension Vol 20: Epidemiology of Hypertension. Ed: Bulpitt CJ. 2000; pp509-526.
11. **Grant PJ**. Risk factors for arterial disease in diabetes: coagulopathy. In: Diabetic Angiopathy. Ed: Tooke JE. Arnold, London, Sydney, New York, 1999; pp93-111.
12. Davies JA, **Grant PJ**. Special aspects of thrombosis in diabetes. In: Cardiovascular Thrombosis - Thrombocardiology and Thromboneurology. 2nd Edn. Eds: Verstraete M, Fuster V, Topol EJ. Lippincott-Raven, Philadelphia, New York, 1998; pp 801-812.
13. **Grant PJ**. Type 2 diabetes mellitus, haemostatic function and insulin resistance: relationship to vascular risk and therapeutic implications. Glucoscope 4, 1997; pp1-27.
14. Mansfield MW, **Grant PJ**. Fibrinolysis and Diabetes Mellitus. In: Fibrinolysis and Disease: Molecular and Hemovascular Aspects of Fibrinolysis. Ed: Glas-Greenwalt P. CRC Press Inc 1995; pp172-183.
15. **Grant PJ**, Prentice CRM. Coronary Artery Disease. In: Haemostasis and Thrombosis. 3rd Edn. Eds Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD. Churchill Livingstone 1994; pp1231-1254.
16. **Grant PJ**. Regulation of haemostasis: The role of arginine vasopressin. In: Desmopressin in Bleeding Disorders. Eds: Mariani, Mannucci, Cattaneo. Plenum Press, New York 1993; pp -11.
17. Davies JA, **Grant PJ**. Acquired bleeding disorders. In: Management of bleeding patients in surgical practice. Eds: Forbes CD, Cushieri A. Blackwell Scientific Publications, Oxford 1993; pp46-67.
18. **Grant PJ**, Prentice CRM. The haematological manifestations of pre-eclampsia. In: Haemostasis and the Kidney. Eds: Remuzzi G, Rossi EC. Butterworths, London, UK 1989 pp259-280.